

















































































Inter-interviewer reliability was high for the overall Adaptive Behavior Composite (.87 for children ages birth through six and .74 for ages 7 through 18 years).<sup>46</sup> While the VABS-II was not specifically designed to assess outcome after neurological injury, several studies have found the VABS to be sensitive to severity of neurological injury.<sup>49, 50</sup> Also, the VABS was used as a primary outcome in completed multicenter, randomized clinical trials in children with infantile spasms<sup>51</sup> and in children with Fragile X Syndrome.<sup>52</sup> It is currently being used as an outcome measure in several NIH funded clinical trials of pediatric patients with a variety of neurological disorders (clinicaltrials.gov). Deficits in functional skills, based on the VABS, have also been noted in several studies of children with cardiac arrest.<sup>49, 53</sup> While the VABS-II is not able to measure subtle differences in skills in very low functioning children, this is true of all measures of neurobehavioral outcome, and compared to other comparable measures,<sup>47, 48</sup> the VABS-II has a greater number of items to assess lower level skills.

Pre-cardiac arrest baseline information will be obtained with the caregiver rating form, and the 3 and 12 month VABS-II assessments will be obtained by interview. Agreement between the interview and caregiver rating form was found to be very high<sup>46</sup> and therefore the two methods can be compared directly.

Follow up interviews will be conducted by telephone. All follow up telephone interviews for VABS-II will be administered centrally by a trained clinician at the Kennedy Krieger Institute (Johns Hopkins School of Medicine, Baltimore, MD).

Telephone interviews, rather than in-person interviews were chosen for several reasons:

- The telephone interview allows for the administration of the VABS through a central site with expertise in outcome assessment. Administration at this central site will enable us to utilize select well trained professionals with direct ongoing oversight by a Psychologist (preferably a Ph.D. Neuropsychologist). This methodology is expected to decrease measurement variability and error.
- The telephone interview allows for increased participation rate for the primary outcome variable, as barriers to returning to a medical center are eliminated. This is especially relevant for those who are severely impaired and thus more challenging to transport. Systematic attrition of the more severely impaired could significantly impact the results of this study. Therefore, every provision is being made to ensure inclusion of these subjects in the primary outcome.

- The VABS is based solely on caregiver information and not on observation of the child, therefore direct observation of the child is not necessary for accurate completion of this measurement. Moreover, reliability between in-person caregiver interview and telephone caregiver interview is extremely high.<sup>54</sup>
- Also, when the VABS was used as a primary outcome in a successfully completed multicenter clinical trial in children with infantile spasms,<sup>51</sup> it was administered at one central site by telephone interview.

Although the primary outcome for this study is based on the VABS-II at 12 months post arrest, the baseline VABS-II score will be used to exclude those with a score less than 70 from analysis of the primary outcome. This approach will enable us to enroll a representative cohort of pediatric ICU patients and to take into account that functional decline may be difficult to quantify in subjects with severe pre-existing neurobehavioral deficits. However, change in VABS-II from baseline to 12 months follow up in survivors will be examined as a secondary outcome in all study subjects.

In order to assess interrater reliability of the VABS II telephone interviews, and prevent variance in ratings over time, the first 4 interviews and thereafter every 10th interview will be recorded for quality assurance. If there is less than 80% agreement on the scoring of the interview, the plan for the recordings will restart with the initial frequency (4 interview followed by every 10th interview). If there is a new interviewer, the frequency will also start with the initial frequency. Staff at KKI will listen to recordings and reconcile any discrepancies within 3 months of the interview. The recordings will be erased immediately after the review and adjudication. Recordings are to be stored in the same manner as all study related documents and will be destroyed as soon as quality assurance activities have taken place

### 6.6.2 PCPC/POPC

The Pediatric Cerebral Performance Category (PCPC) and the Pediatric Overall Performance Category (POPC) scales have been recommended for reporting outcome following cardiac arrest in children.<sup>11</sup> As a consequence, the PCPC and POPC have been used in all the major outcome studies of childhood cardiac arrest.<sup>16, 17, 19, 55, 56</sup> The PCPC provides a rating of neurological functioning, whereas the POPC provides a rating of overall health.

Both the PCPC and POPC can be reliably rated pre and post arrest based on a brief conversation with the child's family or medical record re-

view. Both measures were designed for children who experience cardiac arrest and are applicable to children who do not survive, those who survive in a vegetative state, and those survivors who are unable to cooperate with neuropsychological testing. These instruments provide a simple measure of overall severity and are correlated with other more lengthy measures of outcome, including the VABS.<sup>57</sup> The limitations of the PCPC and POPC are that they do not have normative data for different age groups. Moreover, the PCPC and the POPC do not allow for detailed measurement of functioning or measurement of subtle changes in function or cognition. Therefore, these measures are included for descriptive purposes only, to enable comparisons with results of other studies that used these measures, and are not a primary or secondary outcome of the study.

### 6.6.3 Neuropsychological Testing

In children, duration of cardiac arrest<sup>49</sup> and of circulatory arrest during heart surgery<sup>58</sup> have been associated with lower performance on measures of overall cognitive ability. Additionally, anoxic brain injury often significantly impacts specific neuropsychological skills, including attention, memory, executive functioning, processing speed and motor functioning.<sup>59, 60</sup> To more fully describe these cognitive outcomes and identify subtler but significant impairments, a brief battery of neuropsychological testing will be administered 12 to 16 months post arrest, by designated psychologists at each study site. Measures were chosen that are sensitive to brain injury, have adequate normative data for the age range, plus good reliability and validity. For all children 5 years 8 months or younger, the Mullen Scales of Early Learning will be employed at 12 months post arrest to obtain a measure of overall cognitive functioning. Since the Mullen only has available data through age 5 8/12th years, for children 5 9/12th through 5 11/12th years, testing will be delayed until they are six years old, which may be as late as 16 months post arrest.

For children 6 years of age or older neuropsychology testing will be administered if the child usually "follow instructions" (question 10, VABS-II Receptive Communication) or usually "point or gesture to indicate preference" (question 10, VABS-II Expressive Communication), or have higher level communication skills. For these children, the 2-subtest version (Vocabulary and Matrix Reasoning) of the Wechsler Abbreviate Scale of Intelligence will be administered to obtain a measure of general cognitive functioning (estimated full scale IQ score). In addition, a battery of specific neuropsychological measures to assess processing speed, attention, learning

and memory, executive functioning (ability to plan, organize, and engage in goal directed behavior), and visual motor functioning will be administered to these children

**Processing Speed.** Processing speed will be measured by coding on the Wechsler Intelligence Scale for Children-IV (WISC-IV) and digit symbol-coding on the Wechsler Adult Intelligence Scale Third Edition (WAIS-III). These are essentially the same task, but coding has normative data available for ages 6 through 16 and digit symbol has normative data available for ages 16 and older. In this study, the coding from the WAIS-III will be used for adolescents 17 years or older at the time of follow up. For this test, the individual copies symbols that are paired with simple geometric shapes or numbers. They use a key to draw the symbols in the correct boxes within a 2-minute time limit. This test is consistently more sensitive to brain damage than other Wechsler battery tests and it is the score that is most likely depressed even when damage is minimal.<sup>61</sup> The test-retest reliability (range 0.67 to 0.81) and interscorer agreement (0.98-0.99) is also good for this test. Coding has been shown to be sensitive to even mild TBI.<sup>61</sup>

**Attention.** Attention will be measured using the Digit Span subtest from the Wechsler Intelligence Scale for Children-IV (WISC-IV) and the Wechsler Adult Intelligence Scale Third Edition (WAIS-III).<sup>62-64</sup> Digit Span is a measure of auditory focused attention and working memory. Part one requires the subject to repeat strings of digits presented by the examiner. The strings are two to nine digits in length and are presented at the rate of one digit per second. For part 2, the examiner again presents increasingly longer strings of digits, but for these items the subject is required to reverse the order of the digits. On the WISC-IV, normative data for Digit Span are available for ages 6 through 16 years. For children 17 years and older at the time of follow up the WAIS-III Digit Span will be used. Research has indicated that digits forward span has been found to fall below normal limits in some patients following head injury, but it is also likely to show return to normal levels during subsequent years.<sup>65, 66</sup> Digit Span backwards has also been shown to be sensitive to many types of brain damage.<sup>61</sup> Digit Span demonstrates good test-retest reliability (0.81 for children and 0.75 for adults) and interscorer agreement (0.98-0.99).<sup>62-64</sup> Previous research has found Digit Span backward to be sensitive to TBI.<sup>61, 65, 66</sup>



**Learning and Memory.** The California Verbal Learning Test - Children's Edition (CVLT-C)<sup>67</sup> and the California Verbal Learning Test - Second Edition (CVLT-II)<sup>68</sup> are supraspan list-learning tasks, that will be used to measure verbal learning and memory. The CVLT-C is comprised of five recall trials of a 15-item word list; the list items belong to 3 semantic categories (Fruits, Clothing, Toys), whereas the CVLT-II is comprised of a list of 16 words in 4 semantic categories. For both tasks, there are five learning trials that followed by a single presentation of a distracter list, a second, novel word list. Learning and memory is assessed by number of words recalled over the 5 learning trials, after presentation of the distracter list (short-delay free and cued recall), after a longer 20-minute delay (long-delay free and cued recall), and on recognition. The CVLT-C has normative data available from ages 5 through 16 years, whereas the CVLT II has normative data available for ages 16 through adulthood. The CVLT-II will only be used in this study for adolescents 17 years of age or older at the time of follow up. According to the standardization manuals, the CVLT-C and CVLT-II have moderate to high internal consistency. In contrast, test-retest variability is variable, with improvement noted during the second administration due to learning effects. Moreover, the CVLT-C and CVLT-II have been associated with severity of brain injury.<sup>68-70</sup>

To measure visual memory, Rey Osterrieth Complex Figure (ROCF)<sup>71, 72</sup> will be employed. This task involves the child drawing a complex geometric figure from memory, after copying the figure. A standardized scoring system will be used to measure the accuracy of the recalled figure based on the overall shape and details of the figure. There is a short delay (approximately 3 minutes) and long delay (approximately 30 minute) recall trial. Additionally, after the 30-minute delay trial, there is a recognition trial in which the child will be asked to choose the correct details. The ROCF will be scored using the Meyers and Meyers Scoring System, which includes normative data for ages 5 years and older.<sup>73, 74</sup> The test has good inter-rater reliability (0.93 to 0.99).<sup>73</sup> Meyers and Lange found that brain injured adults performed significantly worse on the ROCF (immediate and delayed recall) compared to psychiatric patients and normal controls.<sup>75</sup>

**Executive Functioning.** We will measure rapid generation of verbal information using the Controlled Oral Word Association Test (COWA).<sup>76</sup> This test requires the individual to generate words that begin with a particular letter as quickly as possible during a one minute trial. Normative data are available for children ages 6 to 13<sup>77</sup> and then 15 to 20 years.<sup>78</sup> For chil-

dren, aged 14 at the time of the evaluation, the normative data for the next youngest group will be used. Test-retest reliability for the COWA is good.<sup>79</sup> Several studies have found the COWA to be highly sensitive among persons with brain injury.<sup>80-82</sup>

In addition to using the ROCF to measure visual memory (as above), we will use the ROCF copy trial to measure executive functions.<sup>71-74</sup> For this task, the child will be asked to copy a complex geometric figure, while the figure is directly in front of the child. A standardized scoring system will be used to measure the accuracy of the copy based on the overall shape and details of the figure. Normative data are available on this measure from age 5 to adulthood. Additionally, test retest reliability and interrater reliability were adequate.<sup>73, 74</sup> The ROCF correlates highly with other measures of visuoconstructional ability.<sup>83, 84</sup> Moreover, the copy of the ROCF has been found to be sensitive to the sequelae of brain injury in children.<sup>85</sup>

**Visual-Motor Functioning.** To measure fine motor dexterity bilaterally, the Grooved Pegboard Test<sup>86</sup> will be administered. This task requires the child to insert pegs into shaped holes on a board. Normative data are available for ages 5 and older.<sup>87</sup> For ages 5 through 8, children are only required to complete two rows of pegs. For older children, all rows are completed.

The Beery Buktenica Developmental Test of Visual-Motor Integration-Fifth Edition (VMI)<sup>88</sup> will be employed to assess ability of children to copy geometric figures of increasing complexity. Normative data are available for ages 2 through 18 years. The 18 year old normative data will be used to calculate standard scores for any individual 19 years of age at the time of the follow up evaluation. Overall odd-even internal consistency is adequate (.88). Inter-scorer reliability is also high (.92). The VMI correlates moderately with overall intellectual abilities. Also, children with neurodevelopmental disabilities associated with low birth weight and spina bifida perform poorly on the VMI compared to typically developing peers.<sup>89, 90</sup>

These measures are summarized in Table 3 on page 44.

#### 6.6.4 Neurological Abnormality Assessment

A detailed standardized neurological exam will be performed in all 12 month survivors by a pediatric neurologist at each site. In order to compare outcomes between groups, and to take into account the different number of exam elements that can be evaluated among survivors of different ages and functional levels, two age-related systematic quantitative scoring systems have

been devised. The scoring systems, Pediatric Resuscitation after Cardiac Arrest (PRCA1 for up to age 3 and PRCA2 for age 3 and older), are derived from the Pediatric Stroke Outcome Measure (PSOM) stroke scale, which is already being used successfully in a multi-center pediatric study of outcome after stroke (in children with sickle cell disease) (ref UO1-NS 042804). Since it is possible that the range in severity of deficits will be greater in the THAPCA study population than in pediatric stroke survivors, the PRCA1 and PRCA2 have an expanded scoring system. All elements of the evaluation represent integral components of age-appropriate neurological evaluation of children. These components include level of consciousness, behavior and mental status, language, cranial nerves, and motor skills. In addition to descriptive material, each exam generates two scores: a global assessment score (0-21 point range), and a normalized cumulative abnormality score.

### 6.6.5 Modifiers of Outcome and Severity Indicators

Since the range of developmental abilities is narrow in very young infants, it is difficult to define those subjects with pre-existing disabilities. Consequently, syndromes and medical conditions typically associated with developmental disabilities will be identified, to verify equal distribution between treatment groups.

Psychosocial variables including family resources<sup>91–93</sup> and family functioning<sup>91, 94</sup> have been consistently associated with outcome following traumatic brain injury. While the relationship between these psychosocial variables and outcome is not as well studied after CA, Bloom (1997) reported that higher socioeconomic status was related to higher cognitive function in both subjects after CA and in controls.<sup>53</sup> We plan to control for the impact of these variables in exploratory analyses. Pre-cardiac arrest baseline family functioning will be measured using the General Functioning Scale of the Family Assessment Device (FAD).<sup>95</sup> This 12 item scale is a self-reported measure with good internal consistency (range of 0.86 – 0.91).<sup>96, 97</sup> It discriminates well between healthy and poor functioning families.<sup>91, 98–100</sup>

Additional severity indicators such as medical or surgical interventions (e.g., need for tracheostomy or mechanical ventilation), rehabilitation services received, and the child's location or level of care needed (e.g., acute care hospital, rehabilitation hospital, nursing home or long term care facility, or at home). These data elements will be collected for descriptive purposes, according to the schedule of assessments outlined in Table 2 on page 36.

Table 3: Neuropsychological battery for subjects older than 6 years.

<b>Domain</b>	<b>Test Name</b>	<b>Constructs Measured</b>	<b>Test Variables</b>
Intelligence	WASI	Overall cognitive ability	Full scale IQ
Processing Speed	WISC-Coding or WAIS-Digit Symbol	Graphomotor speed	Number of symbols copied in time limit
Attention	WISC or WAIS-Digit Span	Attention span Verbal working memory	Total number of items recited correctly
Learning and Memory	CVLT-C or CVLT-II  ROCF - Recall and Recognition	Verbal learning  Verbal memory  Visual memory	Number of words recalled in trials 1 to 5 Short term and long term recall Recognition memory Short term and long term recall Recognition memory
Executive Functioning	ROCF - Copy  COWA	Visual organization  Novel verbal generation	Total accuracy score Total number of words generated
Visual-Motor Functioning	Grooved Pegboard Test  VMI	Fine motor dexterity  Graphomotor accuracy	Time to place all pegs in the board Total accuracy score

### 6.6.6 Family Burden

To assess the impact of the child's health status on the family, the Child's Health Questionnaire (CHQ)<sup>101</sup> and the young child's version of this measure, the Infant/ Toddler Quality of Life Inventory (ITQOL)<sup>102</sup> will be used. On both measures, scales assessing the impact of the child's health condition on parent activities and the impact of the child's health on the parent's emotional status will be employed. Additionally, in the children 5 and older, a third scale assessing limitations in family activities as a result of the child's health status will also be employed. The total score for each of these scales will be converted to a score from 0-100 to allow for comparability between the two measures. The family activities and emotional burden scales of the ITQOL and CHQ have yielded significant differences between healthy children and those with a variety of disease states<sup>103, 104</sup> and between healthy children and children following traumatic injury.<sup>105</sup>

## 7 Detailed Study Interventions

The study interventions will begin in the intensive care unit as soon as possible after informed consent is received. Cardiac arrest patients in the emergency department will be expeditiously transferred to the PICU. Therapeutic hypothermia will not be induced in the emergency department. The setting of the patient's study cardiac arrest (IH vs OH) will be identified, after which the patient will be randomized to a study treatment group (hypothermia or normothermia) in the respective THAPCA Trial (THAPCA-OH or THAPCA-IH). The intervention time period covers the cooling, hypothermia, and rewarming time periods and the interval to 120 hours from the time intervention begins for both arms. Temperature control will be implemented with the Blanketrol III cooling unit (if the Blanketrol III is not available or is already in use, a Blanketrol II can be substituted) and appropriate patient size Maxi-Therm Lite mattresses. Temperature control will use the servo-control mode of the Blanketrol III. The Blanketrol III (and the Blanketrol II) cooling unit and blankets are manufactured by Cincinnati SubZero (CSZ), Cincinnati, OH, in accordance with all applicable Federal regulations. The Blanketrol II has been utilized safely in adult and neonatal clinical trials of therapeutic hypothermia (32 to 34 °C), and the Blanketrol III is the most current model. These prior populations represent the extremes of age ranges for the intended THAPCA Trial (Newborns and Adults vs Pediatric age groups). In prior studies there were no reports of significant skin injury or other complications associated with cooling using

Blanketrol II cooling units.

## 7.1 Hypothermia

Patients randomized to receive therapeutic hypothermia (hypothermia group) will have a target temperature of 33 °C plus or minus 1 °C (32 to 34 °C). Hypothermia will be induced using the Blanketrol III cooling unit and Maxi-Therm Lite blankets placed below and over each patient. No internal cooling procedures or devices will be used (e.g., gastric lavage, intravascular cooling catheter). Based on newborn and adult reports that used the Blanketrol II cooling unit, we expect to achieve the target temperature range within 1 to 4 hours of initiating cooling procedures.<sup>30, 106</sup> For the NICHD Neonatal study, cooling was achieved within 90 minutes<sup>30</sup> and in an adult TBI study, 2.8 hours (1.1 to 4.5 hr range) was reported.<sup>106</sup>

For patient safety, dual central temperature measurements will be performed. A temperature sensing esophageal probe and temperature sensing Foley catheter (or rectal temperature probe) will be placed for temperature monitoring prior to initiation of cooling. Please note: the esophageal probe is the preferred primary probe which will be connected to the Blanketrol unit. However, in the event that an esophageal probe is not judged to be feasible, the Foley catheter or rectal probe may be used as the primary probe and the remaining probe will be the secondary probe which will be connected to the bedside monitor. For patient safety, the *lowest* value will be assumed correct if there is a discrepancy in measurements. If there is a discrepancy of greater than 2 °C between the two measurements, the temperature probes should be inspected for proper positioning and function. The patient's temperature will be monitored continuously and recorded every 30 minutes until central temperature is 33 °C. If the patient is 33 degree at the time of therapy initiation, the temperature will be monitored every 30 minutes for at least one hour. Thereafter, the temperature will be recorded every hour until rewarming begins.

The hypothermia group will be sedated with midazolam and fentanyl. Other benzodiazepines and narcotics may alternatively be used at the clinical site's discretion. The hypothermia group will be paralyzed with vecuronium until the therapeutic hypothermia temperature range is achieved. Vecuronium for paralysis will be held after the initial cooling period and utilized only as needed for shivering unresponsive to the sedation/analgesia protocol described in Section 7.5 on page 49.

Once the patient has achieved the goal temperature (32 to 34 °C), the mattress placed on top of the patient may be moved, however, the mattress

underneath the patient will be left in place. Nursing staff will adjust the Blanketrol III unit as needed to maintain a temperature in the goal range. The hypothermia group will then be maintained in the goal temperature range for 48 hours. Rewarming will then occur over approximately 16 hours (0.7 °C every 4 hours) to normothermia (36.0 °C), which should occur at approximately 72 hours after intervention begins. Temperature will again be recorded every 30 minutes during the rewarming period.

From 72 hours or end of rewarming until 120 hours (end of day 5), the hypothermia group will be maintained in the normothermic range (36-37.5 °C) using the Blanketrol III, and temperature will be recorded every four hours. After 120 hours, temperature management will be according to the normal practice of the clinical care team.

## 7.2 Normothermia

Patients randomized to receive the normothermic control therapy (normothermia group) will have a target temperature of 36.75 (effectively 36.8) plus or minus 0.75 degrees Celsius (36.0 to 37.5 °C). Similar to the hypothermia group, each patient will be placed on a Blanketrol III cooling mattress (Maxi-Therm Lite) set to the appropriate temperature. Once the patient has achieved the goal temperature (36-37.5 °C), it will be maintained with the mattress.

For patient safety, dual central temperature measurements will be performed. A temperature sensing esophageal probe and temperature sensing foley catheter (or rectal temperature probe) will be placed for temperature monitoring. For patient safety, the *highest* value will be assumed correct if there is a discrepancy in measurements. If there is a discrepancy of greater than 2 °C between the two measurements, the temperature probes should be inspected for proper positioning and function. The patient's temperature will be monitored continuously and recorded every 30 minutes until central temperature is 36.8 °C. Thereafter, the temperature will be recorded every hour through 72 hours then every four hours through 120 hours. For study purposes, the temperature measurement closest to the hour should be recorded.

The normothermia group will be sedated with midazolam and fentanyl. Clinical shivering will be treated the same as with the hypothermia group with midazolam and fentanyl dosing as needed. Other benzodiazepines and narcotics may alternatively be used at the clinical site's discretion. See Section 7.5 on page 49 for a detailed description of sedation and neuromuscular blockade therapies.



Throughout the intervention period, nursing staff will adjust the Blanketrol III unit as needed to maintain a temperature in the goal range. The normothermia group will be maintained in the goal temperature range through 120 hours. This corresponds to the hypothermia, rewarming, and normothermia time periods for the hypothermia group. After 120 hours, temperature management will be according to the normal practice of the clinical care team until hospital discharge.

For subjects randomized to the normothermia group with central temperatures below the normothermic range at the time of randomization, slow rewarming to 36 °C at a rate not to exceed 0.5 °C per hour will be initiated. For patients with temperatures greater than 37.5 °C at the time of randomization, the Blanketrol III unit will be used to cool the subject to 37.5 °C. Ibuprofen or other non-steroidal anti-inflammatory drugs that interfere with platelet function are prohibited for use in patients under this protocol. Acetaminophen may be administered in a dose of 10-15 mg/kg if the clinical team determines there exists no contraindication to its use. If body temperature exceeds 38.0 °C in spite of acetaminophen and Blanketrol III cooling, the clinical care team will administer vecuronium (0.1-0.2 mg/kg) once to assist in cooling to normothermia.

### 7.3 Temperature Monitoring

Central temperature monitoring will be required during this study as alternative methods are not reliable. Core body temperature will be measured at two sites for safety, esophageal and either bladder or rectal temperature. In addition to monitoring subject temperature as described below, the water temperature of the Blanketrol III will be monitored and recorded at the same frequency as the subject central temperatures.

Esophageal probe placement will be in the distal third of the esophagus away from the airway. The appropriate sized esophageal temperature probe should be placed just prior to initiating cooling. Using the upper incisors as the marker, the following formula will be used to calculate the distance to insert the probe:  $0.25 \times ht \text{ (cm)} + 4.5 \text{ (cm)} = \text{insertion distance in cm.}$ <sup>107</sup> Proper position will be determined by chest x-ray. Repositioning will be done as needed.

NOTE: Temperature sensing foley catheters as well as temperature sensing esophageal catheters contain metal and may need to be removed prior to an MRI. Each site will need to establish MRI compatibility of temperature sensing catheters. If data are not available, the catheters will be removed at the time of MRI and replaced after leaving the MRI suite.



Temperature will be monitored continuously and recorded hourly through 72 hours and then every 4 hours thereafter through 120 hours. During the initial time to target temperature (hypothermia or normothermia) it will be recorded every 30 minutes. It will also be recorded every 30 minutes during the rewarming period for the hypothermia group. Temperature management after the initial 120 hours will be according to the usual PICU clinical practice at each site. Review of the minimum and maximum daily temperatures, including the measurement site, will be recorded through 10 days (240 hours).

#### **7.4 Vascular Access**

Secure venous access will be required to safely administer fluids and other medications such as inotrope/vasopressor infusions. The standard practice in PICUs is placement of a temporary central venous catheter. A variety of other central venous access type catheters will also be acceptable. A central venous catheter (CVC) may be pre-existing (acute or chronic line such as a Broviac) or peripheral inserted central catheter (PICC line) during the intervention time period so that intravenous fluids and medications may be administered as needed post arrest.

#### **7.5 Management of Sedation and Analgesia**

The use of sedatives and analgesia will be as similar as is clinically feasible in the hypothermia and normothermia groups. Previous adult clinical trials utilized midazolam with or without fentanyl for sedation and analgesia. These agents are well known to practitioners in emergency department and intensive care settings where they are commonly utilized for a variety of indications. Midazolam and fentanyl by continuous infusion supplemented by intermittent dosing will be used for the time intervals corresponding to initial cooling, 48 hours of sustained temperature, and 16 hours of rewarming for both groups.

After the period of cooling and rewarming, which will occur at approximately 72 hours in each group, sedation and analgesia use will be at the discretion of the primary clinical team caring for the patient. Information on agents utilized up to 120 hours (end of day 5) will be recorded.

##### **7.5.1 Sedation**

Midazolam is the sedative agent recommended, but not required, for use in this study. A loading dose of 0.1 mg/kg (100 mcg/kg) of midazolam will

be administered for both groups at the time the interventions are initiated. This will be repeated as needed to achieve a Ramsay score of at least 5 (sluggish response to light tap). A continuous IV infusion of midazolam at 100 mcg/kg/hr will be initiated and maintained at this rate or greater during the initial 4 hour period corresponding to time to cool in the hypothermia group. If required, up to two additional doses of midazolam 0.1 mg/kg (100 mcg/kg) may be given. The infusion rate can then be increased by 50 mcg/kg/hr as needed to achieve a Ramsay sedation score of 5.

If the Ramsay score is 6 (no response) after the first four hours of the intervention, the midazolam drip will be weaned by 50 mcg/kg/hr to achieve a Ramsay score of 5. Lowest infusion dose in the initial 24 hours will be 50 mcg/kg/hr. After 24 hours, the midazolam infusion may be weaned to off if there is no clinical shivering, patient temperature is in the appropriate target range, and the goal for sedation/analgesia is obtained (Ramsay score of 5).

Other benzodiazepines (e.g., lorazepam) may be used as an alternative to midazolam at the clinical site's discretion. However, the level of sedation should be based on the Ramsay targets outlined here.

### 7.5.2 Analgesia

Fentanyl is the analgesic agent recommended, but not required, for use in this study. A loading dose of 2 mcg/kg will be administered for both groups at the time the interventions are initiated. Continuous infusion of fentanyl will begin at 2 mcg/kg/hr and maintained at this rate during the initial 4 hour period corresponding to time to cool in the hypothermia group. If required, up to two additional doses of fentanyl 1 mcg/kg may be given. The infusion rate can then be increased by 1 mcg/kg/hr as needed to achieve a Ramsay sedation score of 5.

If the Ramsay score is 6 (no response) after the first four hours of the intervention, the fentanyl drip will be weaned by 1 mcg/kg/hr to achieve a Ramsay score of 5. The lowest infusion dose in the initial 24 hours will be 1 mcg/kg/hr. After 24 hours, the fentanyl infusion may be weaned to off if there is no clinical shivering, patient temperature is in the appropriate target range, and the goal for sedation/analgesia is obtained (Ramsay score of 5).

Other narcotics (e.g., morphine, remifentanyl) may be used as an alternative to fentanyl at the clinical site's discretion. However, the level of analgesia should be based on the Ramsay targets outlined here.

## 7.6 Use of Neuromuscular Blockade

Vecuronium is the recommended, but not required, neuromuscular blocker for the THAPCA Trials. A paralytic loading dose of 0.1-0.2 mg/kg (100-200 mcg/kg) will be administered to patients randomized to hypothermia to facilitate cooling. Repeated doses of vecuronium will be administered as needed to maintain paralysis until the patient is cooled to the therapeutic range (32-34 °C).

Once therapeutic hypothermia is achieved, neuromuscular blockade is not required, except for as needed to control shivering resistant to sedative/analgesic agents and rewarming without clinical shivering. If a cooled patient begins to rewarm above 34.5 °C in spite of the absence of clinical shivering, vecuronium in a dose of 0.1-0.2 mg/kg (100-200 mcg/kg) would be administered immediately, and continued until the patient cools to the therapeutic range (32-34 °C). Neuromuscular blockade may also be used for other aspects of care at the discretion of the primary care team (such as ventilator asynchrony).

Other non-depolarizing agents may be used during cooling and to control shivering based on the above parameters at the clinical site's discretion.

## 7.7 Management of Glucose and Insulin

An explicit protocol for management of glucose and nutrition is not part of the current protocol at this time. We are aware that large clinical trials of explicit glucose control protocols are ongoing or planned in both adults and pediatric populations at this time. Should information from properly conducted clinical trials become available, which demonstrates efficacy and safety of an explicit protocol approach to glucose management in children, we will consider amending this protocol at that time.

The optimal glucose concentration range following pediatric cardiac arrest and in the more general pediatric critical care population is not known at the time of writing this protocol. It is not known, for example, whether a tight glucose range protocol utilizing insulin would be detrimental in a post arrest pediatric population. In adult populations, there is evidence suggesting hyperglycemia may be associated with poorer neurological outcome after various neurological insults.<sup>108-113</sup> Causality has not been established, however. Furthermore, RCTs in heterogeneous adult ICU settings have so far reported conflicting findings related to tight protocol directed glucose control. Van den Berghe initially reported in a Belgium adult surgical ICU population, tight glucose control to be associated with reduced mortality.<sup>114</sup>

A more recent report by the same investigator reported glucose control not to be associated with reduced mortality in a medical ICU population.<sup>115</sup> A multicenter German RCT (VISEP) of intensive insulin therapy in severe adult sepsis population did not demonstrate efficacy.<sup>116</sup> Of note, this trial was stopped early because of no benefit and high rate of hypoglycemia in the treated group (12% versus 2%). No clinical trials have been conducted to assess explicit protocol directed glucose management and survival in a pediatric ICU population. In pediatric animal models, maintaining glucose levels in a low level range was not reported to improve neurological outcome.<sup>117</sup>

It should be noted that prior adult and neonatal hypothermia RCTs did not report glucose management protocols with the exception of Bernard<sup>28</sup> who stated a glucose less than 180 mg/dl was a goal. There are no animal or human data on the effects of tight glucose control combined with hypothermia on clinical outcomes. Hypothermia is known to be associated with both hyperglycemia and improved neurological outcome.

A potential safety issue exists with hypothermia and insulin use. Serum potassium measurements are known to decrease with therapeutic hypothermia cooling and then increase during the subsequent rewarming period. Insulin is known to significantly decrease serum potassium. If insulin is administered for hyperglycemia associated with hypothermia, it is likely to be associated with worsening of hypokalemia and require additional supplements of large amounts of potassium. On rewarming, this may result in a more exaggerated rise in serum potassium measurement. Therefore, the approach to be recommended for sites in the THAPCA Trials will be to pay special attention to serum potassium and glucose concentrations, and manage glucose, potassium, and insulin administration according to usual clinical practice for each PICU, avoiding extremes of glucose and potassium.

## 7.8 Hemodynamic Management

Blood pressure will be monitored by an arterial line. This is the usual standard practice in PICUs for a post arrest pediatric patient who would meet the study entry criteria. Secure central venous access will be required for participation in this study. This is common practice for the majority of post arrest patients in order to be able to safely and reliably administer fluids, inotropic/vasopressor agents, etc.

It would be desirable to describe an explicit hemodynamic management algorithm for subjects enrolled in THAPCA, but this is untenable due to the diversity of the post arrest pediatric patient population, the multiple etiologies of cardiac arrest, and other comorbid conditions that would be

represented in a typical pediatric population. Of note, explicit hemodynamic protocols were not described in the adult and neonatal RCTs, which demonstrated efficacy of hypothermia for cardiac arrest or HIE.

In general, goal blood pressure for each case will be maintained in a range normal for age and optimized for other factors such as coexisting conditions as determined by the clinical care team. The clinical care team will determine the optimal preload, afterload, contractility and heart rate for each case enrolled in THAPCA. Fluids including blood products or diuretics will be administered as needed to optimize preload. Inotropic and/or vasopressor agents will be administered as clinically indicated for contractility and blood pressure augmentation. Optimal heart rate will also be determined by the bedside clinical care team. This includes treatment of cardiac arrhythmias. The effects of hypothermia on hemodynamics in adult and neonatal trials have usually been related to heart rate with little impact on blood pressure.<sup>118</sup> Bradycardia is commonly associated with decreased oxygen consumption in hypothermia treated cases.<sup>119</sup> In pediatric TBI trials tachycardia was observed in some hypothermia treated patients and responded to fluid administration.<sup>34</sup>

## 7.9 Management of Mechanical Ventilation

The requirement of mechanical ventilation support following cardiac arrest is a study inclusion criteria. It would be desirable to describe an explicit mechanical ventilator management algorithm for subjects enrolled in this study, but this is untenable because of the diversity of potential etiologies, clinical conditions, and comorbidities represented in a typical pediatric population. In general, hyperventilation should be avoided and PaCO<sub>2</sub> should be maintained in a normal physiologic range for age unless the primary care team determines the patient would benefit from a different range. Arterial blood gas values will not be corrected for temperature and will reported at 37 °C . It is a common practice in the PICU setting to use a lung protective strategy by limiting tidal volume and peak inspiratory or plateau pressure. The optimal FiO<sub>2</sub> and PEEP for the clinical case will be determined by the primary care team. The use of high frequency oscillation (HFO) after randomization is permitted. The clinical care team may administer other support therapies such as inhaled nitric oxide (NO) as clinically indicated.

## 7.10 Fluid and Renal Management

After cardiac arrest, patients are at high risk of renal injury that progresses to renal insufficiency or failure. In general, one would limit exposure to nephrotoxic drugs when other agents are available. Urine output less than 1 cc/kg/hr in infants and children and less than 30 cc/hr in adolescents may be inadequate. The primary caregiver team will determine the optimal preload range for a given patient and administer fluids and/or give diuretics as needed. Initiation and type of dialysis modalities if needed will also be determined by the clinical care team.

## 7.11 Seizure Management

The occurrence of clinical and electrographic seizures from the time of randomization through Day 7 will be recorded in the database. General guidelines for evaluation and treatment of either a clinical or an electrographic seizure are summarized as follows. A check of glucose, calcium, and electrolytes would generally be performed if not recently available. A benzodiazepine agent (i.e. lorazepam, midazolam, diazepam) would commonly be administered to stop acute seizure activity. Many patients would also receive a full loading dose of phenobarbital or phenytoin equivalent (20 mg/kg) to prevent recurrence or stop ongoing seizures. A follow-up EEG would be obtained as soon as feasible to verify that there are no on-going electrographic seizures. If there are electrographic seizures noted, these would usually be treated with additional anticonvulsant dosing, according to protocols or care management at each unit.

## 7.12 Special Issues of ECMO

Temperature regulation on ECMO does not require use of surface cooling (Blanketrol III unit with cooling mattresses). The desired temperature will be ordered and set by the bedside ECMO specialist by changing the temperature of the heat exchanger. Special considerations need to be made for the sedation, analgesia, and neuromuscular blockade of patients on ECMO during the intervention phase of the study. The bioavailability of midazolam and fentanyl may be reduced due to possible membrane oxygenator absorption. For patients on ECMO, lorazepam and morphine may be substituted for midazolam and fentanyl. Lorazepam will be given as a bolus of 0.1 mg/kg (100 mcg/kg) as needed to achieve a Ramsay score of 5. This will be followed by intermittent dosing of 0.1 mg/kg as needed.

Morphine will be administered as a bolus of 0.1 mg/kg (100 mcg/kg) as needed to achieve a Ramsay score of 5 or greater. Thereafter, morphine will be administered by continuous infusion beginning at 30 mcg/kg/hr. The infusion dose should be increased by 10 to 30 mcg/kg/hr only after 2 doses of morphine (0.1 mg/kg (100 mcg/kg)) are required.

Paralysis will not be required for ECMO patients unless clinical shivering is observed that is not responsive to sedation/analgesia with lorazepam and morphine.

Due to the propensity for bleeding in the ECMO patient, only one central temperature recording device is required in this population. Either a temperature sensing esophageal probe, Foley catheter or rectal probe can be used. If the clinical center has ECMO equipment that allows for the blood temperature to be measured within the circuit, then this can be substituted for a central temperature recording device (esophageal probe, Foley catheter or rectal probe).

### 7.13 Other Therapy Guidelines

All other therapies administered for both hypothermia and normothermia groups during the times corresponding to initial cooling, hypothermia maintenance, and rewarming periods will be according to the clinical care team.

## 8 Study Data Collection

Clinical data will be collected at the time of enrollment, throughout the intervention period, during the initial hospital stay and at the time of hospital discharge or death. Follow-up information including assessment of neurobehavioral outcomes will be collected at three and 12 months. This section provides a summary of the data that will be collected.

### 8.1 Screening, Enrollment and Randomization Period

Patients will be screened by the clinical investigator in the emergency department and in-hospital settings. Parents or legal guardians of potential subjects will be asked for permission to enter the trial, and the subject will be enrolled and randomized within six hours of ROSC/ROC. During this period patients will be evaluated for inclusion and exclusion criteria and demographic information will be collected. Demographic information will include: date of birth, gender, race, and ethnicity. If the patient meets all

inclusion and exclusion criteria and consent is obtained, the patient will be randomized into the study.

## 8.2 Baseline Period

Baseline data elements will be collected on all patients who have been enrolled and randomized into the study. Information to be collected during this period include a medical and surgical history, a physical examination, hospital and PICU admission information, cardiac arrest information, vital signs, evaluation of mental status, and infection status. Safety laboratories to measure serum chemistry, coagulation parameters, and hematologic parameters will also be collected at baseline.

## 8.3 Intervention Period (0 to 120 Hours)

Study interventions will begin after randomization. During the intervention period, vital signs will be monitored for all patients. Safety laboratories to measure serum chemistry, coagulation parameters, and hematologic parameters will also be collected. Information on daily chest x-rays will also be collected. Chest x-rays are performed routinely on patients after cardiac arrest to assess for signs of new infiltrates and to determine proper positioning of tubes including the esophageal temperature probe. The results of all blood, urine and respiratory cultures during the intervention period will be recorded. Adverse events, concomitant medications, and procedures and therapies administered will be recorded for both groups.

## 8.4 Post Intervention Through Discharge

After the intervention period, patients will be monitored according to standard PICU clinical practice for the participating site. Patients will be reviewed daily for their minimum and maximum temperatures through day 10 or hospital discharge, whichever is earlier. The results of all blood, urine and respiratory cultures conducted up to seven days after cardiac arrest will be recorded. Concomitant medications will be recorded from the time of randomization through day 7. Select procedures and therapies will be recorded through hospital discharge. Blood products received within seven days of arrest will be recorded. Adverse events will be recorded from the time of randomization through Day 14. Adverse events that have not resolved by Day 14 will be followed until resolution or hospital discharge, whichever is earlier. If the Adverse Event has not resolved at the time of hospital discharge, the Research Team should follow the guidelines for AE follow-up outlined



in section 11.2.6 of the protocol. PICU and hospital discharge information will be captured.

### 8.5 Day 28 Status

The vital status of the patient will be recorded on day 28. If the patient has been discharged to home prior to day 28, the parents may be contacted if all other efforts to determine patient mortality have been exhausted.

### 8.6 Three Month Follow Up

Caregivers will be contacted at three months post arrest and will be asked the status of the patient, location of the patient, and if the patient has undergone any additional procedures or therapies. The caregiver will be asked to provide information on family burden, the patient's global function, POPC, and PCPC. The VABS-II assessment will be done at this time. If the respondent is the child's treating healthcare professional the information on family burden will not be collected. All telephone follow up at three months will be conducted centrally by staff at the Kennedy Krieger institute (Johns Hopkins School of Medicine, Baltimore, MD) to assure uniform performance of the VABS-II assessment. In order to assess interrater reliability of the VABS II telephone interviews, and prevent variance in ratings over time, a subset of interviews (every 10th interview) will be recorded. Recorded interviews will be reviewed and rescored by Dr. Slomine. Discrepant scores will be adjudicated through discussion between Dr. Slomine and the psychometrician.

The three month follow up has several purposes. First, the contact will help with subject retention by maintaining communication with the family. Second, the three month assessment will be used to test our primary endpoint conclusions for robustness with respect to missing data (see Section 9.2 on Page 59). Third, it is of exploratory interest to determine if there is a trajectory of improvement between three months and 12 months.

### 8.7 12 Month Follow Up

Parents will be contacted at 12 to 16 months post arrest and will be asked the status of the patient, location of the patient, and if the patient has undergone any additional procedures or therapies. The parents will be asked to provide information on family burden, the patient's global function, POPC, PCPC, and VABS-II assessment. In addition to measures administered over

the phone, the patient will have a neuropsychological evaluation and neurological assessment performed at the study site at 12 to 16 months post arrest.

All telephone follow up will be conducted centrally by staff at the Kennedy Krieger Institute (Johns Hopkins School of Medicine, Baltimore, MD). In order to assess interrater reliability of the VABS II telephone interviews, and prevent variance in ratings over time, a subset of interviews (every 10th interview) will be recorded. Recorded interviews will be reviewed and rescored by Dr. Slomine. Discrepant scores will be adjudicated through discussion between Dr. Slomine and the psychometrician.

## 9 Data Analysis

### 9.1 General Analytic Issues

THAPCA will be analyzed according to the intention to treat principle, wherein all subjects randomly assigned to a treatment arm will be counted in that arm regardless of adherence to protocol or possible crossover to the other treatment arm. Therefore, this clinical trial will assess whether an initial strategy of hypothermia leads to different rates of death or poor neurological outcome than an initial strategy of normothermia. As THAPCA consists of two separate clinical trials, the alpha level for analysis of each trial is 0.05. All tests will be two-tailed.

### 9.2 Primary Analysis

The primary endpoint of each THAPCA trial is survival with good neurobehavioral outcome at 12 months post arrest. The Vineland Adaptive Behavior Scales (VABS-II) will be used to provide a standardized, quantifiable measure of neurobehavioral function in survivors. Poor neurobehavioral functioning is defined as a standardized VABS-II score less than 70 at 12 months. Children with a pre-cardiac arrest baseline VABS-II standardized score less than 70 will be included in the trials but will be excluded from analysis of the primary outcome. Pre-cardiac arrest baseline VABS-II information will be completed retrospectively by the caregiver (as soon as possible after enrollment to decrease retrospective bias), and the 12 month VABS-II assessment will be conducted centrally by telephone interview by the Kennedy Krieger Institute (Johns Hopkins School of Medicine, Baltimore, MD).

Differences between the two study arms with respect to this binary outcome will be evaluated using a chi-square test for each of the two THAPCA Trials separately. The rate ratio comparing survival with good neurobehavioral outcome in the hypothermia arm vs. the normothermia arm and its 95% confidence interval will also be described. Patients with a baseline VABS-II score less than 70 will be excluded from the primary analysis, but included in analyses of secondary and safety endpoints.

As all participating centers will be trained in the delivery of both arms of the study protocol, it is expected that any treatment effect should be reasonably consistent (while not uniformly so) across centers. Therefore, a secondary analysis will employ the Mantel-Haenszel test to quantify treatment effect adjusted by center. The Breslow-Day test (which we recognize will have limited power, as the number of subjects within most centers will be quite low) will be used to assess if there is evidence that treatment effect varies across center.

Missing data will be a non-negligible issue in the primary analysis. It is expected that vital status (alive or dead) will be known for almost all patients. The majority of missing data will consist of detailed neurobehavioral information. While the primary outcome analysis will use subjects with available data for the primary endpoint (complete patients), we will also report analysis results using various methods to estimate missing data including last observation carried forward (LOCF) and imputation approaches. The three month follow up will provide a better basis upon which to test our conclusions for robustness with respect to missing data. We will use the LOCF method using the three month observations, and if the three month and 12 month outcomes are highly correlated for complete patients, then the three month observation may enable a better multiple imputation-based robustness analysis.

### 9.3 Secondary Analyses

Secondary endpoints of each THAPCA trial are:

1. Survival at 12 months post cardiac arrest;
2. Change in neurobehavioral function from pre-cardiac arrest baseline to 12 month measurement (VABS II);

For survivors only,

3. Neuropsychological scores at 12 month evaluation;

#### 4. Neurological abnormality scores at 12 month evaluation.

Mortality over time will be quantified and described using standard survival analysis techniques including generation of Kaplan-Meier curves and comparing these curves between treatment arms via the logrank test. Survival at 12 months will also be evaluated as a binary outcome using the chi-square test. We expect that almost all subjects will have vital status available at 12 months.

The overall change in VABS-II from baseline to 12 months will be evaluated using a linear regression model with 12-month VABS-II as the outcome, and assigned treatment as a predictor along with baseline VABS-II score. Because the distributions may be substantially skewed, we will examine significance levels and confidence intervals for the treatment effect achieved with the nonparametric Wilcoxon rank-sum test for consistency with the findings of the parametric approach. The Wilcoxon rank-sum test will be based on ranks assigned to the differenced scores (12 month minus baseline). If outcomes unexpectedly appear to have substantially differing distribution shapes between treatment arms, resampling techniques will be used to test significance of, and estimate magnitude of, differences in median outcome between treatment arms.

Neuropsychological testing results for the Mullen Scales of Early Learning (children  $\leq 5$  years 8 months) will be measured as continuous outcomes. Comparison between the study groups will employ a two-sample t-test if appropriate, or alternatively, the Wilcoxon rank-sum test if basic normality assumptions are not met. As detailed in Table 3 on page 44, for patients 6 years and older there is a battery of neuropsychological tests, with separate outcome measures for each test. Comparison between groups will be based on ranks and employ the Wilcoxon rank-sum test. Patients who do not meet minimum requirements to be tested will be assigned the lowest rank for a test; patients who are tested but are unable to meet the test's basal requirements will be given the second lowest rank for that test; all other patients will receive a rank based on the actual score achieved for that test.

The neurological abnormality scores will be measured as continuous outcomes for those who complete the exam. Comparison between the study groups will employ a two-sample t-test if appropriate, or alternatively, the Wilcoxon rank-sum test if basic normality assumptions are not met.

Narrative descriptors for each element of the PRCA (Section 6.6.4 on page 43) will also be analyzed by study investigators to characterize patterns of neurological dysfunction in survivors (e.g. specific movement disorders or

cognitive deficits).

## 9.4 Safety Analyses

Safety endpoints of this study are:

1. All-cause 28 day mortality;
2. Incidence of culture proven infection (blood, urine, respiratory, or other) within 7 days of cardiac arrest;
3. Incidence of arrhythmias within 7 days of cardiac arrest;
4. Blood products required within 7 days of cardiac arrest. Blood products are defined specifically here to include red blood cells, platelets, fresh frozen plasma, and cryoprecipitate.

Differences between the two study arms with respect to these binary outcomes will be evaluated using a separate chi-square test for each of the THAPCA Trials. Appropriate exact tests will be employed in the case of excessively small expected cell sizes. Rate ratios and 95% confidence intervals will also be described. A secondary analysis will employ the Mantel-Haenszel test to quantify the treatment effect adjusted by center, and the Breslow-Day test (which we recognize will have limited power, as the number of subjects within most centers will be quite low) will be used to assess if there is evidence that treatment effect varies across center.

## 9.5 Additional Exploratory Analyses

The primary goal of a randomized trial is to assess treatment effect with respect to various outcomes, and evidence for a treatment effect will be the focus of the primary publications from these trials. Predefined primary and secondary outcomes will be clearly noted as such in relevant reports. However, regardless of the primary study finding, THAPCA will generate a database of uniformly, carefully followed pediatric subjects after cardiac arrest, with details of their post-arrest management. Thus, it will be of interest to use this database to perform exploratory analyses of the trajectory of recovery (by comparing three month and 12 month VABS-II), or factors associated with outcomes. An example would be post hoc identification of patient characteristics, or patient management strategies, associated with a larger treatment effect. These studies will employ appropriate approaches including linear and logistic regression, Cox proportional hazards regression,

and appropriate variants of the mixed model to summarize outcomes over time. Assigned treatment will be included in these analyses as appropriate. Reports of these analyses will be clearly described as exploratory rather than formal hypothesis testing.

## 9.6 Power Analysis for Primary Outcome

As stated above, we believe it is appropriate to use an alpha level of 0.05 for each of the two THAPCA Trials, and that two-sided tests are appropriate for the study scenario. From previous studies, we would estimate primary outcome rates to be in the range of 80% for the out-of-hospital normothermia arm, while among the in-hospital subjects, a lower outcome rate would be expected, along the lines of 65% in the normothermia arm. Table 4 and Table 5 on the next page show the total number of subjects needed for the THAPCA-OH and THAPCA-IH Trials to achieve statistical power between 70% and 90% under various treatment effects. The treatment effect is noted as absolute effect size in these tables. Thus, for example in the out-of-hospital trial, an absolute effect size of 20% implies hypothermia improves the outcome rate from 80% to 60%, and in this instance 182 subjects would be required for 80% power. These numbers are not adjusted for interim data monitoring, but such adjustment is nearly negligible if conservative stopping boundaries are employed (Section 9.7 on the facing page).

Based on HD044955 cohort pilot data and the size and number of sites participating in the current study, we anticipate enrolling between 150 to 250 patients per year for a total enrollment of 750 to 950 patients (300 to 350 out-of-hospital arrests in the THAPCA-OH Trial and 450 to 600 in-hospital arrests in the THAPCA-IH Trial). This will give an effective sample size of 250 to 300 out-of-hospital arrests and 400 to 500 in-hospital arrests after adjustment for loss to follow up (10%) and excluding patients with a baseline VABS-II score less than 70. We therefore expect these trials to have substantial power (80 to 85%) to detect absolute treatment effects of 15% or greater among out-of-hospital subjects, and absolute treatment effects of 15% or greater in the in-hospital subjects.

Table 4: Sample Size Needed (Total) to Detect Various Treatment Effects, Assuming Event Rate in Normothermia Arm of 80% (Out of Hospital), Two-Sided Test with  $\alpha=0.05$

Absolute Effect Size	Power = 70% ( $\beta = 0.3$ )	Power = 75% ( $\beta = 0.25$ )	Power = 80% ( $\beta = 0.2$ )	Power = 85% ( $\beta = 0.15$ )	Power = 90% ( $\beta = 0.1$ )
5%	1800	2014	2266	2580	3600

*continued on next page*

Table 4: *continued*

Absolute Effect Size	Power = 70% ( $\beta = 0.3$ )	Power = 75% ( $\beta = 0.25$ )	Power = 80% ( $\beta = 0.2$ )	Power = 85% ( $\beta = 0.15$ )	Power = 90% ( $\beta = 0.1$ )
10%	500	558	626	710	822
15%	242	272	302	342	396
20%	148	162	182	204	236
25%	100	110	122	138	158
30%	74	82	90	100	116

Table 5: Sample Size Needed (Total) to Detect Various Treatment Effects, Assuming Event Rate in Normothermia Arm of 65% (In Hospital), Two-Sided Test with  $\alpha=0.05$ 

Absolute Effect Size	Power = 70% ( $\beta = 0.3$ )	Power = 75% ( $\beta = 0.25$ )	Power = 80% ( $\beta = 0.2$ )	Power = 85% ( $\beta = 0.15$ )	Power = 90% ( $\beta = 0.1$ )
5%	2392	2680	3020	3442	4016
10%	630	704	790	898	1044
15%	294	326	366	414	480
20%	170	188	210	238	274
25%	112	124	138	156	178
30%	80	88	98	110	126

## 9.7 Interim Analyses and Stopping Rules

This study will be monitored by the Data Safety Monitoring Board (DSMB) appointed by the funding institute (National Institutes of Health). The DSMB will have final jurisdiction regarding frequency of meetings, and appropriate formal monitoring boundaries for study stopping in terms of superiority. In this application, we present what we believe is an appropriate interim analysis plan. A detailed version of this plan will be submitted to the DSMB for approval and possible modification prior to the beginning of study enrollment.

Interim monitoring for superiority of one treatment approach over the other will clearly be appropriate in this study. While many investigators might expect hypothermia to be superior to normothermia, we believe that symmetric monitoring boundaries are appropriate as one cannot rule out a detrimental relative effect of either strategy.

Numerous clinical trials have found early treatment differences that diminished or even reversed as more subjects were enrolled. In a multicenter clinical trial, it is not unusual for early recruitment to be confined to a subset of centers that receive early IRB approval or have a smoother run-

in phase; the experience at these centers may differ from others. Also, a “learning curve” in delivering the study therapies, at some or all centers, is not inconceivable and has been specifically noted for therapies such as hypothermia.<sup>120</sup> Because of these issues, we strongly recommend monitoring boundaries that are conservative at the early looks at the data; we believe that O’Brien-Fleming-type boundaries,<sup>121</sup> implemented using the Lan-deMets flexible alpha spending function approach,<sup>122</sup> are appropriate for this study setting.

As this is an expensive study to conduct, early stopping of either or both of the THAPCA Trials for futility (low chance that a treatment effect is found if the trial continues) is a consideration. A conditional power approach, wherein the chance of the study finding a treatment effect (given the data accrued thus far in the study) under various assumed true scenarios is assessed, may be appropriate for the DSMB to address futility issues if this becomes necessary.<sup>123</sup> This approach, which requires careful consideration of what treatment effect scenarios are realistic given the study data themselves, encourages dialogue and discussion among DSMB members.

The projected accrual period in this study is five years. We assume that the DSMB will meet prior to study launch, and then twice per year during patient accrual. While flexible  $\alpha$  spending will be used, we assume here for illustration purposes that there will be four meetings at which the DSMB will perform interim analysis, and that 10%, 25%, 50%, and 80% of study data (technically, of total statistical information for the primary outcome) are available at the respective meetings. Thus, in our illustration, there would be four interim analyses, with an additional final analysis of the study data if the study is not terminated early. While there is no doubt that the DSMB will integrate the results of the study in the out-of-hospital and in-hospital cohorts in their decision making, we generate stopping boundaries independently for these separately powered trials, in line with this study’s analytic strategy.

It is helpful to simulate how many subjects will be required, since it is possible that enrollment for one or both trials (in-hospital and out-of-hospital arrests) will be curtailed early, because of evidence of superiority. As indicated in Section 9.6 on page 62, the precise effect size is not known. The discussions of stopping rules and properties below assume that the effect size for the primary analysis has been correctly estimated in the study power calculations. All calculations assume a two-sided  $\alpha = 0.05$ .

The possibility of stopping early is dependent on total information available at the time of each interim look. These chances of stopping early are identical for the THAPCA-OH and THAPCA-IH Trials, assuming each has



the same power and amount of information at a given look at the data. If the sample size is large enough to enable 90% power, it is more likely that a trial would be stopped early, because more statistical information is available than if the sample size is only large enough to enable 80% power. Table 6 shows the actual monitoring boundaries (expressed in terms of p-values), and expected probability of stopping the study (for benefit) at each look if the true effect size is precisely as postulated in the study power calculations.

It is important to note that sample size adjustments are required to adjust for the interim analyses, although these are so slight as to be nearly negligible. For example, if one of the substudies is designed to have 90% power and 500 subjects are required based on no interim analysis, the required sample size increases to 512 under the meeting schedule discussed above.

It is evident from these simulations that if the treatment effects are at least as large as expected *a priori*, the THAPCA Trials have a substantial chance of stopping early due to superiority, despite the conservative stopping boundaries that are pre-specified for each. Also, it should be noted that some “ $\alpha$  spending” occurs from interim analyses, and if either trial is carried to completion, the final determination of overall significance of the primary endpoint at the  $\alpha = 0.05$  level will require using a significance level of 0.0426 for the final analysis.

Table 6: Probability of Early Stopping at Interim Analyses

Analysis	Information	2-sided p value	Probability of Stopping, Power = 80% ( $\beta = 0.2$ )	Probability of Stopping, Power = 90% ( $\beta = 0.1$ )
First	10%	$\leq 0.000000014$	negligible	negligible
Second	25%	$\leq 0.000015$	0.2%	0.4%
Third	50%	$\leq 0.003$	16.7%	25.5%
Fourth	80%	$\leq 0.0235$	44.0%	49.0%
Final	100%	$\leq 0.0426$	19.2%	15.1%

## 10 Human Subjects Protection

### 10.1 IRB Review and Communications

This protocol, the parental permission, and child assent forms must be reviewed and approved by each clinical center’s IRB before the study begins at that site. In addition, the Data Coordinating Center (DCC) must have

documentation of current IRB approval at all times during the study. The Data Coordinating Center must also have a copy of the informed permission and child assent forms that were approved by the IRB for each clinical center before enrollment will be permitted at the clinical center.

## **10.2 Informed Consent**

### **10.2.1 Parental Permission**

This protocol requires that parents or other legally empowered guardians sign a parental permission form. The parent or legal guardian will be informed about the objectives of the study and the potential risks.

### **10.2.2 Child Assent**

Subjects who are eligible for THAPCA are comatose, and child assent will not be possible at the time of study enrollment. However, during follow up after discharge from the PICU, issues about assent become applicable. Children who are capable of giving assent and who are alert and competent, will be asked, following an age-appropriate discussion of risks and benefits, to give assent to the study for collection of follow up information. Assent will be waived if the child is too young, has a severely reduced mental age, decreased level of consciousness, psychological problems, or other legitimate reasons as judged by the Institutional Review Board at each site.

### **10.2.3 Subject Consent**

Subjects who are eligible for THAPCA are comatose and under 18 years of age. If a subject attains the age of 18 years during the study intervention period, it will not be possible to obtain informed consent from the subject. During the follow up after discharge from the PICU, 18 year old subjects who are alert and competent and capable of giving consent will be asked, following an appropriate discussion of risks and benefits, to give consent to the study for collection of follow up information. Subject consent will be waived if the subject has a severely reduced mental age, decreased level of consciousness, psychological problems, or other legitimate reasons as judged by the Institutional Review Board at each site.

## **10.3 Risks and Benefits**

Potential complications of hypothermia are addressed in the next two sections (Sections [10.4.1 on the next page](#) and [10.4.2 on page 68](#)). The potential

benefit of the intervention (hypothermia) is that it may improve overall survival, and may result in improved neurobehavioral outcome after pediatric cardiac arrest. Subjects assigned control(normothermia) therapy in this interventional trial may also benefit from having body temperature rigorously controlled in the normal range. In usual practice at most children's hospitals, central temperature is not rigorously monitored and controlled. To minimize the risks of this trial, all subjects will have their temperature controlled by the Blanketrol III cooling unit and appropriately-sized Maxi-Therm Lite mattresses.

#### **10.4 Risk of Surviving with Worse Neurobehavioral Outcome**

It is known that a significant number of children who have sustained cardiac arrest currently survive with neurological injury. It is expected that a significant number of children participating in THAPCA Trials will also survive with neurological injury regardless of whether they receive the actively maintained normothermic control therapy or therapeutic hypothermia. We do not know at this time whether the chance of surviving with brain injury is more likely in the cooled group or the normothermic control group. The informed consent shall reflect this information.

##### **10.4.1 Complications Reported in Previous Studies**

Several clinical trials have now been conducted in both newborn and adult populations that observed therapeutic hypothermia to be safe, so we do not expect clinically important complications associated with hypothermia to be observed in the THAPCA Trials.

Shankaran<sup>30</sup> reported an RCT of 205 newborns with birth asphyxia of which 102 were cooled with the Blanketrol II cooling unit for 72 hours. No increased occurrence of cardiac arrhythmia, bleeding, skin changes or death during the cooling period was observed. Additionally, there was no increase in blood stream infection during the hospital course. Other complications that were similar between the hypothermia and control groups were as follows: hypotension, persistent pulmonary hypertension, oliguria/anuria, hepatic dysfunction, disseminated intravascular coagulopathy, hypoglycemia, and hypocalcemia.

The neonatal CoolCap study<sup>29</sup> reported elevated glucose in hypothermia group vs control newborns (7.6 vs 5.4 mmol/L), which resolved spontaneously in 24 hours. Scalp edema occurred more commonly in head

cooled patients 32/108 vs. 1/110 controls, and resolved shortly after the end of cooling. There were no major cardiac arrhythmias, venous thrombosis, severe hypotension, or unanticipated serious adverse events reported. Other complications not increased in cooled cases included: hypotension, coagulopathy, prolonged coagulation times, abnormal renal function, hyponatremia, hypokalemia, platelet count less than 100,000/mcl, metabolic acidosis, respiratory distress, systemic infection, hemoconcentration, hypoglycemia, hypocalcemia, and clinical seizures. Liver function elevation was less in cooled cases.

Polderman reported a large adult experience of therapeutic hypothermia with the Blanketrol II cooling unit and mattresses. No increased risk of intracranial hematomas, acute renal failure, clinically significant cardiac complications, pulmonary complications, or deep venous thrombosis were reported.<sup>106</sup> The average duration of cooling was 4.8 days with a range of 1 to 21 days.

Bernard<sup>28</sup> reported an adult cardiac arrest RCT in which cooling was done with cold packs and cooling mattresses. No differences in platelet count or WBC during 12 hours of cooling in adult cardiac arrest cases were observed. Potassium levels were observed to be slightly lower at 6 hours in cooled patients compared to normothermic controls (3.6 vs. 4.0 mmol/L;  $p=0.06$ ) and were stable during the period of cooling. On rewarming, potassium levels were greater in cooled patients (4.5 vs 3.9 mmol/L) at 24 hours. Glucose levels were also noted to be higher in cooled patients than normothermic cases (16.2 vs 10.5 mmol/L). The hyperglycemia resolved following rewarming.

#### 10.4.2 Minimizing Risk of Complications in THAPCA Trials

There are several elements of this study design that will help minimize risks to subjects. The exclusion criteria eliminate certain populations that might be at higher risk for complications. These include patients on extremely high pressor infusions, sickle cell anemia, cryoglobulinemia, pregnancy, skin conditions, and patients with Glasgow Coma Score motor scale indicating an ability to localize pain or obey commands. Patients with terminal illnesses or progressive degenerative conditions will also not be eligible for enrollment.

Risk to subjects will also be minimized by the nature of the PICU clinical setting. Patients will be hospitalized in intensive care units and monitored closely for potential complications and adverse events as a part of usual clinical care. Patients will be assessed as per usual clinical care for development of skin injury or excessive cooling which could occur with use of the cooling

blanket. Each clinical site will be instructed to follow the instructions on the Blanketrol III unit and standard of care at their respective institutions. The study investigator will be contacted for central temperatures of 31.0 °C or less. The importance of temperature control will be emphasized in the training session and in the manual of operations. The Blanketrol III unit is equipped with a temperature control safety system that measures and controls the temperature which also will help protect the patient from harm. Temperature control will be implemented in all subjects using the servo-control mechanism available on the Blanketrol III.

We will provide training for clinical investigators and coordinators regarding potential complications of therapeutic hypothermia, study procedures, and the importance of temperature monitoring and maintaining therapeutic temperature ranges. Additional details on potential complications and the appropriate steps to be taken in the event of a complication are outlined below.

**Excessive cooling below the therapeutic range.** This complication will be treated by increasing the Blanketrol III temperature so that the patient warms to the therapeutic range (32 to 34°C). Excessive cooling below the therapeutic range in the THAPCA Trials could result in life-threatening cardiac arrhythmias. If cooling below the therapeutic range occurs in patients randomized to receive hypothermia, the patient will be rewarmed to the therapeutic range of 32 to 34°C immediately. Arrhythmias will be managed according to standard AHA PALS guidelines. Excessive cooling will be avoided by utilizing two central temperature probes (esophageal and bladder or rectal) and monitoring subject temperature on a continual basis. The temperature of the water in the Blanketrol III will also be monitored and recorded, and temperature control in all subjects will use the servo-control mechanism available with the Blanketrol III. The patient will not be cooled below 32-34 °C therapeutic range. The study investigator will be contacted for central temperatures of 31.0 °C or less. In the event that the temperature difference between central measures is greater than 1.0 °C, the study investigator will be also be notified.

**Cardiac arrhythmias.** Serious cardiac arrhythmias are not expected to occur unless the temperature falls well below 30 °C. If a clinically significant arrhythmia develops and persists, then the patient would be rewarmed to normal range if determined by the clinical care team to be necessary.

**Infection.** Infection rates are expected to be high in both groups of subjects (normothermia and hypothermia groups), based on our prior cohort study data of cardiac arrest patients. The clinical team will utilize antibiotics per their usual clinical site practice in the post arrest population. The THAPCA Trials will monitor both hypothermia and normothermia (control) groups for blood stream and urinary infections as outlined in Section 6.3 of the protocol. In the event of a positive culture or suspicion of possible infection, appropriate antibiotics will be initiated based on the clinical care team's hospital experience.

**Bleeding.** Bleeding will be monitored by measuring the volume per kg of blood products (red blood cells, platelets, fresh frozen plasma, cryoprecipitate) administered during the first seven days. We will also track the number of surgical interventions for bleeding during the first 7 days. Patients with life threatening bleeding or severe coagulopathies will not be eligible for this trial. Life threatening bleeding during the study will be managed per the clinical care team with rewarming to the normal range. Prior TBI studies did not observe bleeding to be more commonly observed in hypothermic patients compared to normothermic patients.

**Alterations of Potassium.** Initiation of cooling has been associated with slight reduction in potassium serum concentration measurement. Serum potassium levels will be measured at baseline and then at least every 6 hours during cooling and the rewarming period. Rewarming has been associated with mild increase in potassium serum concentration measurement. Therefore, the clinical team will remove potassium from the IV fluids during rewarming and supplement as needed during this period. Thereafter, the clinical care team will measure potassium based on their normal unit practice.

**Multiple organ failure and death.** Patients who have had cardiac arrests are at high risk for development of multiple organ failure and death. In our previous cohort study, the mortality rate was nearly 50%. Seizures following cardiac arrest varied between 14-26% for in-hospital and out-of-hospital cases. Blood stream infection was also high in the cohort study.

In summary, for the therapeutic hypothermia group of the THAPCA Trials, we do not expect higher rates of adverse effects to be observed based on findings from neonatal and adult RCTs using therapeutic hypothermia for HIE or cardiac arrest.

## 10.5 Data Security and Subject Confidentiality

All evaluation forms, and reports will be identified only by a coded number to maintain patient confidentiality. All records will be kept in a locked/password protected computer. All computer entry and networking programs will be done with coded numbers only. Clinical information will not be released without the written permission of the patient, except as necessary for monitoring by the Federal funding institution (NHLBI), the DCC, or other governmental regulatory bodies.

The data coordinating center (DCC) at the University of Utah has a dedicated, locked server room within its offices, and the building has 24 hour on-site security guards. The DCC has a state-of-the-art computer infrastructure and coordinates its network infrastructure and security with the Health Sciences Campus (HSC) information systems at the University of Utah. This provides the DCC with effective firewall hardware, automatic network intrusion detection, and the expertise of dedicated security experts working at the University. Network equipment includes three high-speed switches and two hubs. User authentication is centralized with two Windows 2003 domain servers. Communication over public networks is encrypted with virtual point-to-point sessions using secure socket layer (SSL) or virtual private network (VPN) technologies, both of which provide at least 128 bit encryption. OpenClinca (OC) is the clinical trials software used at the DCC, and eRoom<sup>TM</sup> is used for communications about the study. It is possible that a different electronic data capture system could be used in the future. OC, eRoom<sup>TM</sup> and other web applications use the SSL protocol to transmit data securely over the Internet.

Direct access to DCC machines is only available while physically located inside the DCC offices, or via a VPN client. All network traffic is monitored for intrusion attempts, security scans are regularly run against our servers, and our IT staff are notified of intrusion alerts. Security is maintained with Windows 2003 user/group domain-level security. Users are required to change their passwords every 90 days, and workstations time out after 10 minutes of inactivity. All files are protected at group and user levels; database security is handled in a similar manner with group level access to databases, tables, and views in Microsoft SQL Server.

The investigators and staff of the data coordinating center are fully committed to the security and confidentiality of data collected for the THAPCA Trials. All personnel at the DCC have signed confidentiality agreements concerning all data encountered in the DCC. Violation of these agreements may result in termination from employment at the University of Utah. In addi-

tion, all personnel involved with DCC data systems have received Human Subjects Protection and HIPAA education.

## 10.6 Health Insurance Portability and Accountability Act

Data elements collected include the date of birth and date of admission. Prior to statistical analyses, dates will be used to calculate patient age at the time of the study events. The final data sets (used for study analyses and archived at the end of the study) will be de-identified, and will exclude these specific dates.

Data elements for race, ethnicity, and gender are also being collected. These demographic data are required for Federal reporting purposes to delineate subject accrual by race, ethnicity, and gender.

Each Clinical Center will be required to obtain informed consent from a legal guardian of eligible patients before the patient is enrolled in the study. For purposes of the DCC handling potential protected health information (PHI) and producing the de-identified research data sets that will be used for analyses, all study sites have been offered a Business Associate Agreement with the University of Utah. Copies of executed Business Associate Agreements are maintained at the DCC.

## 10.7 Record Retention

For federally funded studies subject to the Common Rule, records relating to the research conducted shall be retained for at least 3 years after completion of the research. Completion of the research for this protocol should be anticipated to include planned primary and secondary analyses, as well as subsequent derivative analyses. Completion of the research also entails completion of all publications relating to the research. All records shall be accessible for inspection and copying by authorized representatives of the regulatory authorities at reasonable times and in a reasonable manner [45 CFR §46.115(b)].

# 11 Data and Safety Monitoring Plan

## 11.1 Data Safety Monitoring Board (DSMB)

THAPCA will have a Data Safety Monitoring Board (DSMB) appointed by the Director of the National Heart, Lung, and Blood Institute (NHLBI). The



DSMB will have a charter, will approve the protocol prior to implementation, and will review interim analyses as described in Section 9.7 on page 63.

The purpose of the DSMB is to advise the Federal funding agency (NHLBI), the THAPCA scientific Principal Investigator (Dr. Moler), and the THAPCA Executive Committee regarding the continuing safety of study subjects and the continuing validity and scientific merit of the study. The DSMB is responsible for monitoring accrual of study subjects, adherence to the THAPCA protocol, assessments of data quality, performance of individual clinical sites, review of serious adverse events and other subject safety issues, and review of formal interim statistical analyses of treatment efficacy. The Data Coordinating Center will send reports relating to these topics to DSMB members ten days prior to each DSMB meeting. We propose that the DSMB will meet twice annually during patient accrual into the THAPCA Trials, although the DSMB will have the discretion to alter meeting timing and frequency. There are no planned DSMB meetings in the last year of the THAPCA project, during which no new patients will be enrolled (but 12 month follow-up will be conducted to obtain the primary outcome.)

The Data Coordinating Center will staff DSMB meetings. The DSMB Executive Secretary, appointed by NHLBI, will produce minutes of the meetings. The minutes will be approved by the DSMB Chairperson and sent to the Director, NHLBI, for acceptance of recommendations. The THAPCA Executive and Steering Committees will then receive the minutes.

## 11.2 Adverse Event Reporting

### 11.2.1 Definitions, Relatedness, Severity and Expectedness

**Definition:** An adverse event (AE) is any untoward medical occurrence experienced by a subject. An event constitutes a disease, a set of related signs or symptoms, or a single sign or symptom.

On each study day, the clinical site investigator will evaluate adverse events. Adverse events not previously documented in the study will be recorded on the adverse event record form. The nature of each experience, date and time (where appropriate) of onset, outcome, course, and relationship to treatment should be established.

**Relatedness:** The suspected relationship between study intervention (use of the temperature control blanket and/or hypothermia) and any adverse event will be determined by the clinical site investigator using the following criteria:

**Not Related:** The event is clearly related to other factors, such as the subject's clinical state, therapeutic interventions, or concomitant drugs administered to the subject.

**Possibly Related:** The event follows compatible temporal sequence from the time of application of the temperature blanket or changes in temperature, but could have been produced by other factors such as the subject's clinical state, therapeutic interventions, or concomitant drugs administered to the subject.

**Probably Related:** The event follows a reasonable temporal sequence from the time of application of the temperature blanket or changes in temperature, and cannot be reasonably explained by other factors such as the subject's clinical state, therapeutic interventions, or concomitant drugs administered to the subject.

**Seriousness:** The severity of clinical adverse events and laboratory abnormalities will be recorded by the clinical site investigator and categorized. A serious adverse event (SAE) is an adverse event that:

- results in death; or
- is life-threatening (the patient was, in the view of the clinical site investigator, in immediate danger of death from the event as it occurred); or
- requires inpatient hospitalization or prolongs and existing hospitalization; or
- results in persistent or significant disability or incapacity; or
- results in congenital anomaly/birth defect); or
- any other event that, based upon appropriate medical judgement, may jeopardize the subject's health and may require medical or surgical intervention to prevent one of the other outcomes listed in this definition.

**Expectedness of the Event:** All adverse events, including serious adverse events, will be evaluated as to whether their occurrence was expected or unexpected. An adverse event is considered expected if it is known to be associated with critical illness following cardiac arrest, the underlying medical condition of the subject, is directly related to study outcome (e.g. death), or is otherwise mentioned in the protocol, informed consent, or other study documents. For this protocol, expected events include:

- mortality (unless believed to be related to cooling)
- hemodynamic instability
- cardiac arrhythmias, including life-threatening rhythms
- electrolyte abnormalities
- metabolic acidosis
- sepsis, infections, or bacteremia
- fever
- bleeding
- seizures
- cerebral edema and other brain injury
- worsening neurological function
- renal dysfunction
- liver dysfunction
- reintubation
- hypoxia
- respiratory distress
- pleural effusions
- pulmonary edema
- anasarca (body edema)
- general pediatric problems related to ICU stay and cardiac arrest
- complications related to the condition that led to cardiac arrest

**Treatment or Action Taken:** For each adverse event, the clinical site will record whether an intervention was required:

- Intervention: Surgery or procedure
- Other Treatment: Medication initiation, change, or discontinuation
- None: No action taken

Finally, the clinical site will record the clinical outcome of each adverse event as follows:

- Death
- Recovered and the patient returned to baseline status
- Recovered with permanent sequelae
- Symptoms continue

### **11.2.2 Time Period for Adverse Events**

For purposes of the THAPCA Trials, adverse events occur following randomization through Day 14. Specifically, events that occur following parental permission to participate in THAPCA, but prior to actual randomization, will not be reported as adverse events. These should be recorded as baseline conditions. Events that occur following discharge from the hospital will not be reported as adverse events. Adverse events that occur between randomization and Day 14 that are not resolved by Day 14 will be followed until resolution or hospital discharge, whichever is earlier. If the event has not resolved by hospital discharge, please see section 11.2.6 of the protocol for further instructions.

### **11.2.3 Data Collection Procedures for Adverse Events**

After patient randomization, all adverse events (including serious adverse events), whether anticipated or unanticipated, will be recorded according to the date of first occurrence, severity, and their duration, as well as any treatment prescribed. Any medical condition present at the time of randomization, recorded in the patient's baseline history at study entry, which remains unchanged or improves, will not be recorded as an adverse event at subsequent evaluations. However, worsening of a medical condition that was present at the time of randomization will be considered a new adverse event and reported.

Abnormal laboratory values that are clinically significant will be recorded as adverse events and the clinical site investigator will assess the severity and relationship to the study. Laboratory values that are abnormal at the time of randomization and that do not worsen will not be recorded as adverse events.

Adverse events will be coded using the MedDRA coding vocabulary. Coding will be done centrally at the DCC because this requires specific training.

### **11.2.4 Monitoring Serious Adverse Events**

The Principal Investigator of the Data Coordinating Center (Dr. Dean) will act as the medical monitor for THAPCA. If Dr. Dean is unavailable, a qualified physician will be designated to fulfill this function. Clinical site investigators or coordinators will report a selected subset of expected serious adverse events to the DCC within 24 hours. A detailed completed report will be required to be sent to the DCC within 3 working days of the event,

and the medical monitor will assess these serious adverse events reported from clinical sites in THAPCA. For each of these serious adverse events, the clinical site will provide sufficient medical history and clinical details for a safety assessment to be made with regard to continuation of the THAPCA Trial. The medical monitor will sign each SAE report after review. All SAE reports will be retained at the DCC, and all SAE reports will be available for review by DSMB members and NHLBI staff via the eRoom<sup>TM</sup> facility.

Serious adverse events that require a written notification of the DCC within 24 hours and a completed written report within three working days of the SAE, and subsequent review by the medical monitor, include the following:

- Mortality
- Infection diagnosed with positive bacterial or fungal culture
- Repeat cardiac arrest
- Life threatening arrhythmias
- Any SAE requiring early cessation of hypothermia
- Any SAE that the clinical site investigator believes should be reported with the supplemental written information.

The other expected serious adverse events that are listed in Section [11.2.1 on page 74](#) do not require written reporting, but should be recorded in the same manner as all adverse events.

In the unlikely event that the medical monitor believes an unexpected and study-related SAE warrants emergent cessation of enrollment in either or both of the THAPCA Trials, NHLBI staff and the DSMB chairperson will be immediately consulted. If these individuals concur with the judgment of the medical monitor, or if the NHLBI staff and the DSMB chairperson cannot be reached expeditiously, the Data Coordinating Center will notify all clinical site investigators to cease enrollment in the trial. Resumption of enrollment will not occur without consent of the THAPCA Executive Committee, the DSMB, and NHLBI staff.

### **11.2.5 Reporting Procedures**

Assuring patient safety is an essential component of this protocol. Each participating investigator has primary responsibility for the safety of the individual subjects under his or her care. All adverse events will be evaluated by the clinical site investigator, and will be classified as noted in Section [11.2.1](#)

. All adverse events occurring after study randomization through Day 14 will be recorded and entered into the electronic data entry system provided by the DCC.

The clinical site investigator will report all *serious, unexpected, and study-related* adverse events to the DCC within 24 hours. A detailed completed report will be required to be sent to the DCC within 3 working days of the event. After receipt of the complete report, the DCC will report such *serious, unexpected, and study-related* adverse events to the NHLBI Program Official or Project Officer in an expedited manner (within 24 hours). In accordance with local IRB requirements, the clinical site investigator may be required to report such events to the IRB in addition to notifying the DCC. In the event that the medical monitor believes that such an event warrants emergent suspension of enrollment in either or both of the THAPCA Trials, and NHLBI staff cannot be reached expeditiously, the Data Coordinating Center will notify all clinical site investigators to suspend enrollment in the trial. Resumption of enrollment will not occur without consent of the THAPCA Executive Committee, the DSMB, and NHLBI staff.

Unanticipated problems (UP) are defined as incidents, experiences, or outcomes that are unexpected, related to participation in the THAPCA Trials, and suggest that the research places subjects at a greater risk of harm than was previously known or recognized. The clinical site investigator will report unanticipated problems to the DCC within 24 hours. A detailed completed report will be required to be sent to the DCC within 3 working days of the event. After receipt of the complete report, the DCC will report these unanticipated problems to the NHLBI Program Official or Project Officer in an expedited manner (within 24 hours). In accordance with local IRB requirements, the clinical site investigator may be required to report such unanticipated problems to the IRB in addition to notifying the DCC. In the event that the medical monitor believes that the unanticipated problem warrants emergent suspension of enrollment in either or both of the THAPCA Trials, and NHLBI staff cannot be reached expeditiously, the Data Coordinating Center will notify all clinical site investigators to suspend enrollment in the trial. Resumption of enrollment will not occur without consent of the THAPCA Executive Committee, the DSMB, and NHLBI staff.

After notification of the NHLBI Program Official or Project Officer, and the DSMB chairperson, of *serious, unexpected, and study-related* adverse events or unanticipated problems (UP), decisions will be made whether to continue the study without change, and whether to convene the entire DSMB for an emergent meeting. If a decision is made to suspend enrollment in

either THAPCA trial, this will be reported to all THAPCA investigators, who will be instructed to report this to their local IRB.

The DSMB will review all adverse events (not necessarily serious, unexpected, and study-related) during scheduled DSMB meetings. The DCC will prepare a Summary Report of Adverse Events within 30 days of its meeting, and this report will be distributed to all THAPCA investigators to be forwarded to the local IRB. The Summary Report will contain the following information:

- A statement that a DSMB review of outcome data, adverse events, and information relating to study performance across all centers took place on a given date;
- A statement as to whether or not the frequency of adverse events exceeded what was expected and indicated in the informed consent;
- A statement that a review of recent literature relevant to the research took place;
- The DSMB recommendation with respect to progress or the need for modification of the protocol or informed consent. If the DSMB recommends changes to the protocol or informed consent, the rationale for such changes and any relevant data will be provided;
- A statement that if safety concerns are identified, the NHLBI Program Officer will communicate these promptly to all THAPCA investigators.

### 11.2.6 Follow-up of Adverse Events

All serious, unexpected and related adverse events, that are unresolved at the time of the patient's termination from the study or discharge from the hospital, will be followed by the investigators until the events are:

- Resolved, subject is lost to follow-up, the adverse event is otherwise explained or has stabilized; OR
- 12 months has passed from the time of randomization

Adverse experiences that begin after discharge from the hospital will not be reported as study adverse events.

## 12 Data Quality Assurance

### 12.1 Data Management

Data will be entered into an electronic data collection (EDC) system to be designed and implemented by the DCC. The Study Coordinator is required

to use hard copies of worksheets for data collection. The paper worksheets should be retained at the clinical center in a secure location until the study is complete and all study publications have been published.

## 12.2 Study Training

A formal training program for investigators and research staff will be held prior to the start of enrollment. The training program will cover regulatory topics including applicable device regulations and good clinical practice. The training will also provide in depth explanations regarding study procedures, device operation, clinical care, adverse event reporting, data entry procedures, quality assurance, site monitoring and the informed consent process. A manual of operations will be provided to each site investigator prior to the start of enrollment. The manual will detail specific information about the study procedures, regulatory information, safety reporting, and other necessary information. Updates and revisions to the manual will be made available electronically. The DCC, in collaboration with the principal investigator, will be the main contact for study questions. The DCC will coordinate phone conferences and/or web conferences at intervals throughout the study to address educational needs. It is also anticipated that the Steering Committee will meet at least twice per year, once in teleconference and once in person. At the physical meeting, it is anticipated that the research coordinators will also be present, and this setting may be used to facilitate ongoing study training.

A team of experts will also be on call to guide sites through enrollment of the first two patients in order to assure that correct study procedures are being followed, and to answer any questions related to administration of the interventions.

## 12.3 Site Monitoring

Clinical trials require monitoring commensurate with the degree of risk involved in participation as well as the size and complexity of the study. Site monitoring will be implemented with actual visits to each site, supplemented by remote site monitoring.

### 12.3.1 Physical Site Monitor Visits

Site monitoring visits are conducted during the study to review patient entry, data quality, and patient safety and to assure regulatory compliance. The ongoing site monitoring visits will include an on-site meeting of the monitor,



the investigator and his/her staff. A site monitor will visit each study site during the study period and review compliance with the study methodology and adherence to Good Clinical Practice guidelines. The site monitor will provide each site with a written report and sites will be required to follow up on any deficiencies.

It is anticipated that the study monitoring visits for this protocol will consist of a site initiation visit (prior to patient enrollment), interim visits, and a close out visit. The site initiation may take place as a group training of site investigators and research assistants.

Interim visits will take place depending on grant budget, site enrollment, and compliance issues identified. The first interim visit will take place when 1 to 5 subjects are enrolled. Subsequent interim visit triggers will be determined and outlined in the site monitoring plan. During interim visits, review of regulatory compliance and documentation, 100% review of consent documentation is anticipated, along with statistically controlled sampling for source verification.

Close out visits will take place after the last subject is enrolled at the site. The close out visit agenda would include resolution of outstanding queries and a review of adverse events, regulatory documentation, and archiving plan.

### **12.3.2 Remote Site Monitoring**

The data center will supplement on-site monitoring with remote monitoring activities. Remote monitoring involves detailed review of the data entered by the site and telephone consultations with the site investigator or coordinator to review safety and data quality. The on site monitoring agenda generally includes source document verification of remote monitoring and the internal site QA performed.

### **12.3.3 Site Monitoring Plan**

A supplemental study-specific monitoring plan, separate from the protocol, will be completed prior to the start of the study which outlines specific criteria for monitoring. This plan will include the number of planned site visits, criteria for focused visits, or additional visits, a plan for chart review, and a follow up plan for non compliant sites. The monitoring plan also describes the type of monitoring that will take place (e.g. sample of all subjects within a site; key data or all data), the schedule of when these activities are to take place, how they are reported, and a time frame to

resolve any issues found. For remote site monitoring, data elements and schedule of monitoring will be determined by the DCC.

## 12.4 Record Access

Patient medical information obtained by this study is confidential, and disclosure to third parties other than those noted below is prohibited. Upon the patient's permission, medical information may be given to his or her personal physician or other appropriate medical personnel responsible for his or her welfare. The medical record must be made available to authorized representatives of the DCC, upon request, for source verification of study documentation. In addition, medical information and data generated by this study must be available for inspection upon request by representatives of the U.S. FDA, Health Canada (the Canadian counterpart of the U.S. FDA), site local health authorities, the DCC and its authorized representative(s), the National Institutes of Health, and the IRB for each study site, if appropriate.

## 13 Publication of Data

Because a large number of sites and investigators will be involved in THAPCA, it is not reasonable to use a traditional authorship structure for study publications. Authorship for this study will be corporate, crediting the group's name (THAPCA Trial Investigators), and also including a byline to credit the participating research networks (PECARN and CPCCRN). Participant roles will be listed in the Appendix. All publications will be reviewed by the PECARN and CPCCRN according to applicable policies in these two networks, the THAPCA Executive Committee, and NHLBI requirements.

## Bibliography

- [1] Sirbaugh PE, Pepe PE, Shook JE, Kimball KT, Goldman MJ, Ward MA, et al. A prospective, population-based study of the demographics, epidemiology, management, and outcome of out-of-hospital pediatric cardiopulmonary arrest. *Ann Emerg Med.* 1999;33(2):174–84.
- [2] Young KD, Gausche-Hill M, McClung CD, Lewis RJ. A prospective, population-based study of the epidemiology and outcome

- of out-of-hospital pediatric cardiopulmonary arrest. *Pediatrics*. 2004;114(1):157–64.
- [3] Schindler MB, Bohn D, Cox PN, McCrindle BW, Jarvis A, Edmonds J, et al. Outcome of out-of-hospital cardiac or respiratory arrest in children. *N Engl J Med*. 1996;335(20):1473–9.
- [4] Ronco R, King W, Donley DK, Tilden SJ. Outcome and cost at a children’s hospital following resuscitation for out-of-hospital cardiopulmonary arrest. *Arch Pediatr Adolesc Med*. 1995;149(2):210–4.
- [5] O’Rourke PP. Outcome of children who are apneic and pulseless in the emergency room. *Crit Care Med*. 1986;14(5):466–8.
- [6] Friesen RM, Duncan P, Tweed WA, Bristow G. Appraisal of pediatric cardiopulmonary resuscitation. *Can Med Assoc J*. 1982;126(9):1055–8.
- [7] Torphy DE, Minter MG, Thompson BM. Cardiorespiratory arrest and resuscitation of children. *Am J Dis Child*. 1984;138(12):1099–102.
- [8] Nichols DG, Kettrick RG, Swedlow DB, Lee S, Passman R, Ludwig S. Factors influencing outcome of cardiopulmonary resuscitation in children. *Pediatr Emerg Care*. 1986;2(1):1–5.
- [9] Barzilay Z, Somekh E, Sagy M, Boichis H. Pediatric cardiopulmonary resuscitation outcome. *J Med*. 1988;19(3-4):229–41.
- [10] Eisenberg M, Bergner L, Hallstrom A. Epidemiology of cardiac arrest and resuscitation in children. *Ann Emerg Med*. 1983;12(11):672–4.
- [11] Zaritsky A, Nadkarni V, Getson P, Kuehl K. CPR in children. *Ann Emerg Med*. 1987;16(10):1107–11.
- [12] Rosenberg NM. Pediatric cardiopulmonary arrest in the emergency department. *Am J Emerg Med*. 1984;2(6):497–9.
- [13] Fiser DH, Wrape V. Outcome of cardiopulmonary resuscitation in children. *Pediatr Emerg Care*. 1987;3(4):235–8.
- [14] Thompson JE, Bonner B, Lower GMJ. Pediatric cardiopulmonary arrests in rural populations. *Pediatrics*. 1990;86(2):302–6.
- [15] Hickey RW, Cohen DM, Strausbaugh S, Dietrich AM. Pediatric patients requiring CPR in the prehospital setting. *Ann Emerg Med*. 1995;25(4):495–501.

- [16] Torres AJ, Pickert CB, Firestone J, Walker WM, Fiser DH. Long-term functional outcome of inpatient pediatric cardiopulmonary resuscitation. *Pediatr Emerg Care*. 1997;13(6):369–73.
- [17] Reis AG, Nadkarni V, Perondi MB, Grisi S, Berg RA. A prospective investigation into the epidemiology of in-hospital pediatric cardiopulmonary resuscitation using the international Utstein reporting style. *Pediatrics*. 2002;109(2):200–9.
- [18] Gillis J, Dickson D, Rieder M, Steward D, Edmonds J. Results of inpatient pediatric resuscitation. *Crit Care Med*. 1986;14(5):469–71.
- [19] Nadkarni VM, Larkin GL, Peberdy MA, Carey SM, Kaye W, Mancini ME, et al. First documented rhythm and clinical outcome from in-hospital cardiac arrest among children and adults. *JAMA*. 2006;295(1):50–7.
- [20] Young KD, Seidel JS. Pediatric cardiopulmonary resuscitation: a collective review. *Ann Emerg Med*. 1999;33(2):195–205.
- [21] Guerguerian A, Nichols D, Sheffner D. Survivors of Cardiac Arrest. *Ped Crit Care Med*. 2003;4[Suppl]:A104–5.
- [22] Thoresen M. Cooling the newborn after asphyxia - physiological and experimental background and its clinical use. *Semin Neonatol*. 2000;5(1):61–73.
- [23] Colbourne F, Corbett D, Zhao Z, Yang J, Buchan AM. Prolonged but delayed postischemic hypothermia: a long-term outcome study in the rat middle cerebral artery occlusion model. *J Cereb Blood Flow Metab*. 2000;20(12):1702–8.
- [24] Hicks SD, DeFranco DB, Callaway CW. Hypothermia during reperfusion after asphyxial cardiac arrest improves functional recovery and selectively alters stress-induced protein expression. *J Cereb Blood Flow Metab*. 2000;20(3):520–30.
- [25] Gunn AJ, Gunn TR, de Haan HH, Williams CE, Gluckman PD. Dramatic neuronal rescue with prolonged selective head cooling after ischemia in fetal lambs. *J Clin Invest*. 1997;99(2):248–56.
- [26] Thoresen M, Satas S, Loberg EM, Whitelaw A, Acolet D, Lindgren C, et al. Twenty-four hours of mild hypothermia in unsedated new-

- born pigs starting after a severe global hypoxic-ischemic insult is not neuroprotective. *Pediatr Res.* 2001;50(3):405–11.
- [27] Group HACAS. Mild therapeutic hypothermia to improve the neurologic outcome after cardiac arrest. *N Engl J Med.* 2002;346(8):549–56.
- [28] Bernard SA, Gray TW, Buist MD, Jones BM, Silvester W, Gutteridge G, et al. Treatment of comatose survivors of out-of-hospital cardiac arrest with induced hypothermia. *N Engl J Med.* 2002;346(8):557–63.
- [29] Gluckman PD, Wyatt JS, Azzopardi D, Ballard R, Edwards AD, Ferriero DM, et al. Selective head cooling with mild systemic hypothermia after neonatal encephalopathy: multicentre randomised trial. *Lancet.* 2005;365(9460):663–70.
- [30] Shankaran S, Laptook AR, Ehrenkranz RA, Tyson JE, McDonald SA, Donovan EF, et al. Whole-body hypothermia for neonates with hypoxic-ischemic encephalopathy. *N Engl J Med.* 2005;353(15):1574–84.
- [31] Eicher DJ, Wagner CL, Katikaneni LP, Hulsey TC, Bass WT, Kaufman DA, et al. Moderate hypothermia in neonatal encephalopathy: safety outcomes. *Pediatr Neurol.* 2005;32(1):18–24.
- [32] Eicher DJ, Wagner CL, Katikaneni LP, Hulsey TC, Bass WT, Kaufman DA, et al. Moderate hypothermia in neonatal encephalopathy: efficacy outcomes. *Pediatr Neurol.* 2005;32(1):11–7.
- [33] Biswas AK, Bruce DA, Sklar FH, Bokovoy JL, Sommerauer JF. Treatment of acute traumatic brain injury in children with moderate hypothermia improves intracranial hypertension. *Crit Care Med.* 2002;30(12):2742–51.
- [34] Adelson PD, Ragheb J, Kanev P, Brockmeyer D, Beers SR, Brown SD, et al. Phase II clinical trial of moderate hypothermia after severe traumatic brain injury in children. *Neurosurgery.* 2005;56(4):740–54; discussion 740–54.
- [35] Hutchison JS, Ward RE, Lacroix J, Hébert PC, Barnes MA, Bohn DJ, et al. Hypothermia therapy after traumatic brain injury in children. *N Engl J Med.* 2008 Jun;358(23):2447–56.

- [36] Stiell IG, Wells GA, Field B, Spaite DW, Nesbitt LP, De Maio VJ, et al. Advanced cardiac life support in out-of-hospital cardiac arrest. *N Engl J Med.* 2004;351(7):647–56.
- [37] Safar PJ, Kochanek PM. Therapeutic hypothermia after cardiac arrest. *N Engl J Med.* 2002;346(8):612–3.
- [38] Nolan JP, Morley PT, Vanden Hoek TL, Hickey RW, Kloeck WGJ, Billi J, et al. Therapeutic hypothermia after cardiac arrest: an advisory statement by the Advanced Life Support Task Force of the International Liaison Committee on Resuscitation. *Circulation.* 2003;108(1):118–21.
- [39] Nolan JP, Morley PT, Hoek TLV, Hickey RW. Therapeutic hypothermia after cardiac arrest. An advisory statement by the Advanced Life Support Task Force of the International Liaison Committee on Resuscitation. *Resuscitation.* 2003;57(3):231–5.
- [40] Donoghue AJ, Nadkarni V, Berg RA, Osmond MH, Wells G, Nesbitt L, et al. Out-of-hospital pediatric cardiac arrest: an epidemiologic review and assessment of current knowledge. *Ann Emerg Med.* 2005;46(6):512–22.
- [41] Bohn DJ, Biggar WD, Smith CR, Conn AW, Barker GA. Influence of hypothermia, barbiturate therapy, and intracranial pressure monitoring on morbidity and mortality after near-drowning. *Crit Care Med.* 1986;14(6):529–34.
- [42] The Pediatric Emergency Care Applied Research Network (PECARN): rationale, development, and first steps. *Pediatr Emerg Care.* 2003;19(3):185–93.
- [43] The Pediatric Emergency Care Applied Research Network (PECARN): rationale, development, and first steps. *Acad Emerg Med.* 2003;10(6):661–8.
- [44] Willson DF, Dean JM, Newth C, Pollack M, Anand KS, Meert K, et al. Collaborative Pediatric Critical Care Research Network (CPCCRN). *Pediatr Crit Care Med.* 2006 Jul;7(4):301–307. Available from: <http://dx.doi.org/10.1097/01.PCC.0000227106.66902.4F>.
- [45] Sparrow S, Balla D, Cicchetti D. *Vineland Adaptive Behavior Scales.* Circle Pines, MN: American Guidance Service; 1984.

- [46] Sparrow S, Cicchetti D, Balla D. Vineland Adaptive Behavior Scales (2nd edition). Circle Pines, MN: AGS Publishing; 2005.
- [47] Bruininks RH, Woodcock RW, Weatherman RF, Hill BK. Scales of Independent Behavior - Revised. Itasca, IL: The Riverside Publishing Company; 1996.
- [48] Harrison P, Oakland T. Adaptive Behavior Assessment System. 2nd ed. San Antonio, TX: The Psychological Corporation, a Harcourt Assessment Company; 2003.
- [49] Morris RD, Krawiecki NS, Wright JA, Walter LW. Neuropsychological, academic, and adaptive functioning in children who survive in-hospital cardiac arrest and resuscitation. *J Learn Disabil*. 1993 Jan;26(1):46–51.
- [50] Fletcher JM, Ewing-Cobbs L, Miner ME, Levin HS, Eisenberg HM. Behavioral changes after closed head injury in children. *J Consult Clin Psychol*. 1990 Feb;58(1):93–98.
- [51] Lux AL, Edwards SW, Hancock E, Johnson AL, Kennedy CR, Newton RW, et al. The United Kingdom Infantile Spasms Study (UKISS) comparing hormone treatment with vigabatrin on developmental and epilepsy outcomes to age 14 months: a multicentre randomised trial. *Lancet neurology*. 2005 Nov;4(11):712–7. Available from: [http://linkinghub.elsevier.com/retrieve/pii/S1474-4422\(05\)70199-X](http://linkinghub.elsevier.com/retrieve/pii/S1474-4422(05)70199-X).
- [52] Torrioli MG, Vernacotola S, Peruzzi L, Tabolacci E, Mila M, Militeri R, et al. A double-blind, parallel, multicenter comparison of L-acetylcarnitine with placebo on the attention deficit hyperactivity disorder in fragile X syndrome boys. *Am J Med Genet A*. 2008 Apr;146(7):803–12.
- [53] Bloom AA, Wright JA, Morris RD, Campbell RM, Krawiecki NS. Additive impact of in-hospital cardiac arrest on the functioning of children with heart disease. *Pediatrics*. 1997 Mar;99(3):390–398.
- [54] Limperopoulos C, Majnemer A, Steinbach CL, Shevell MI. Equivalence reliability of the Vineland Adaptive Behavior Scale between in-person and telephone administration. *Physical & Occupational Therapy in Pediatrics*. 2006 Jan;26(1-2):115–27. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/16938828?dopt=abstract>.

- [55] Horisberger T, Fischer E, Fanconi S. One-year survival and neurological outcome after pediatric cardiopulmonary resuscitation. *Intensive Care Med.* 2002;28(3):365–8.
- [56] Lopez-Herce J, Garcia C, Rodriguez-Nunez A, Dominguez P, Carrillo A, Calvo C, et al. Long-term outcome of paediatric cardiorespiratory arrest in Spain. *Resuscitation.* 2005;64(1):79–85.
- [57] Fiser DH, Long N, Roberson PK, Hefley G, Zolten K, Brodie-Fowler M. Relationship of pediatric overall performance category and pediatric cerebral performance category scores at pediatric intensive care unit discharge with outcome measures collected at hospital discharge and 1- and 6-month follow-up assessments. *Crit Care Med.* 2000;28(7):2616–20.
- [58] Bellinger DC, Jonas RA, Rappaport LA, Wypij D, Wernovsky G, Kuban KC, et al. Developmental and neurologic status of children after heart surgery with hypothermic circulatory arrest or low-flow cardiopulmonary bypass. *N Engl J Med.* 1995 Mar;332(9):549–555.
- [59] Caine D, Watson JD. Neuropsychological and neuropathological sequelae of cerebral anoxia: a critical review. *J Int Neuropsychol Soc.* 2000 Jan;6(1):86–99.
- [60] Hopkins RO, Tate DF, Bigler ED. Anoxic versus traumatic brain injury: amount of tissue loss, not etiology, alters cognitive and emotional function. *Neuropsychology.* 2005 Mar;19(2):233–242. Available from: <http://dx.doi.org/10.1037/0894-4105.19.2.233>.
- [61] Lezak M. *Neuropsychological assessment* (3rd edition). New York: Oxford University Press; 1995.
- [62] Wechsler D. *Wechsler Intelligence Scale for Children: Administration and Scoring Manual* (4th edition). San Antonio, Texas: The Psychological Corporation; 2003.
- [63] Wechsler D. *Wechsler Intelligence Scale for Children: Technical Manual* (4th edition). San Antonio, Texas: The Psychological Corporation; 2003.
- [64] Wechsler D. *Wechsler Adult Intelligence Scale: Administration and Scoring Manual* (3rd edition). San Antonio, Texas: The Psychological Corporation; 1997.



- [65] Lezak MD. Recovery of memory and learning functions following traumatic brain injury. *Cortex*. 1979 Mar;15(1):63–72.
- [66] Uzzell BP, Langfitt TW, Dolinskas CA. Influence of injury severity on quality of survival after head injury. *Surg Neurol*. 1987 May;27(5):419–429.
- [67] Delis D, Kramer J, Kaplan E, Ober B. California Verbal Learning Test - Children. San Antonio, TX: The Psychological Corporation; 1994.
- [68] Delis D, Kramer J, Kaplan E, Ober B. California Verbal Learning Test (2nd edition). San Antonio, TX: The Psychological Corporation; 2000.
- [69] Yeates KO, Blumenstein E, Patterson CM, Delis DC. Verbal learning and memory following pediatric closed-head injury. *J Int Neuropsychol Soc*. 1995 Jan;1(1):78–87.
- [70] Salorio CF, Slomine BS, Grados MA, Vasa RA, Christensen JR, Gering JP. Neuroanatomic correlates of CVLT-C performance following pediatric traumatic brain injury. *J Int Neuropsychol Soc*. 2005 Oct;11(6):686–696. Available from: <http://dx.doi.org/10.1017/S1355617705050885>.
- [71] Rey A. Psychological examination of traumatic encephalopathy. *Archives de Psychologie*. 1941;28:286–340.
- [72] Osterrieth P. Le test de copie d'une figure complexe. *Archives de Psychologie*. 1944;30:206–356.
- [73] Meyers J, Meyers K. The Meyers scoring system for the complex figure and recognition trial: professional manual. Odessa, Florida: Psychological Assessment Resources; 1995.
- [74] Meyers J, Meyers K. The Meyers scoring system for the complex figure and recognition trial: supplemental manual. Odessa, Florida: Psychological Assessment Resources; 1996.
- [75] Meyers J, Lange D. Recognition subtest for the complex figure. *The Clinical Neuropsychologist*. 1994;5:361–76.
- [76] Spreen O, Benton A. Neurosensory Center Comprehensive Examination for Aphasia (NCEA). Victoria: University of Victoria Neuropsychology Laboratory; 1969, 1977.

- [77] Gaddes WH, Crockett DJ. The Spreen-Benton aphasia tests, normative data as a measure of normal language development. *Brain Lang.* 1975 Jul;2(3):257–280.
- [78] Yeudall L, Fromm D, Reddon J, Stefanyk W. Normative data stratified by age and sex for 12 neuropsychological tests. *J Clin Psychol.* 1987;42:918–946.
- [79] des Rosiers B, Kavanagh D. Cognitive assessment in closed head injury: stability, validity and parallel forms for two neuropsychological measures of recovery. *Int J Clin Neuropsych.* 1987;9:162–173.
- [80] Spreen O, Strauss E. *A compendium of neuropsychological tests.* New York, NY: Oxford University Press; 1998.
- [81] Mutchnick MG, Ross LK, Long CJ. Decision strategies for cerebral dysfunction IV: determination of cerebral dysfunction. *Arch Clin Neuropsychol.* 1991;6(4):259–270.
- [82] Ewing-Cobbs L, Levin HS, Eisenberg HM, Fletcher JM. Language functions following closed-head injury in children and adolescents. *J Clin Exp Neuropsychol.* 1987 Oct;9(5):575–592.
- [83] Poulton RG, Moffitt TE. The Rey-Osterreith Complex Figure Test: norms for young adolescents and an examination of validity. *Arch Clin Neuropsychol.* 1995 Jan;10(1):47–56.
- [84] Demsky Y, Carone DA, Burns WJ, Sellers A. Assessment of visual-motor coordination in 6- to 11-yr.-olds. *Percept Mot Skills.* 2000 Aug;91(1):311–321.
- [85] Matthews L, Anderson V, Anderson P. Assessing the validity of the Rey Complex Figure as a diagnostic tool: Accuracy, recall and organizational strategy score in children with brain insult. *Clin Neuropsych Assessment.* 2001;2:85–9.
- [86] Reitan R. *Manual for Administration of Neuropsychological Test Batteries for Adults and Children;* 1969. Indianapolis University Medical Center.
- [87] Knights RM, Moule AD. Normative data on the motor steadiness battery for children. *Percept Mot Skills.* 1968 Apr;26(2):643–650.

- [88] Berry K, Beery N. The Beery-Buktenica Developmental Test of Visual-Motor Integration (5th edition): Administration, Scoring, and Teaching Manual. Minneapolis, MN: NCS, Pearson, Inc.; 2004.
- [89] Zelkowitz P, Papageorgiou A, Allard M. Relationship of rehospitalization to cognitive and behavioral outcomes in very low birth weight and normal birth weight children. *J Devel Behav Ped.* 1994;15:179–85.
- [90] Wills KE, Holmbeck GN, Dillon K, McLone DG. Intelligence and achievement in children with myelomeningocele. *J Pediatr Psychol.* 1990 Apr;15(2):161–176.
- [91] McCarthy ML, MacKenzie EJ, Durbin DR, Aitken ME, Jaffe KM, Paidas CN, et al. Health-related quality of life during the first year after traumatic brain injury. *Arch Pediatr Adolesc Med.* 2006 Mar;160(3):252–260.
- [92] Schwartz L, Taylor HG, Drotar D, Yeates KO, Wade SL, Stancin T. Long-term behavior problems following pediatric traumatic brain injury: prevalence, predictors, and correlates. *J Pediatr Psychol.* 2003 Jun;28(4):251–263.
- [93] Wade SL, Taylor HG, Yeates KO, Drotar D, Stancin T, Minich NM, et al. Long-term parental and family adaptation following pediatric brain injury. *J Pediatr Psychol.* 2006;31(10):1072–1083. Available from: <http://dx.doi.org/10.1093/jpepsy/jsj077>.
- [94] Yeates KO, Taylor HG, Drotar D, Wade SL, Klein S, Stancin T, et al. Preinjury family environment as a determinant of recovery from traumatic brain injuries in school-age children. *J Int Neuropsychol Soc.* 1997 Nov;3(6):617–630.
- [95] Epstein N, Baldwin L, Bishop D. The McMaster Family Assessment Device. *J Marital Fam Ther.* 1983;9:171–80.
- [96] Byles J, Byrne C, Boyle MH, Offord DR. Ontario Child Health Study: reliability and validity of the general functioning subscale of the McMaster Family Assessment Device. *Fam Process.* 1988 Mar;27(1):97–104.
- [97] Miller I, Epstein N, Bishop G D and Keitner. The McMaster Family Assessment Device: Reliability and validity. *J Marital Fam Ther.* 1985;11:345–56.

- [98] Stein D, Williamson DE, Birmaher B, Brent DA, Kaufman J, Dahl RE, et al. Parent-child bonding and family functioning in depressed children and children at high risk and low risk for future depression. *J Am Acad Child Adolesc Psychiatry*. 2000 Nov;39(11):1387–1395.
- [99] Clark AF, Barrett L, Kolvin I. Inner city disadvantage and family functioning. *Eur Child Adolesc Psychiatry*. 2000 Jun;9(2):77–83.
- [100] Clark MS, Smith DS. Changes in family functioning for stroke rehabilitation patients and their families. *Int J Rehabil Res*. 1999 Sep;22(3):171–179.
- [101] Landgraf J, Abetz L, Ware J. The CHQ user’s manual (1st edition). Boston, MA: The Health Institute, New England Medical Center; 1996.
- [102] Landgraf J. The Infant/Toddler Child Health Questionnaire: Conceptual Framework, Logic Content, and Preliminary Psychometric Results. Boston, MA: Health Act; 1994.
- [103] Klassen A, Landgraf J, Lee S, Barer M, Raina P, Chan H, et al. Health related quality of life in 3 and 4 year old children and their parents: preliminary findings about a new questionnaire. *Health Qual Life Outcomes*. 2003 Dec;1(1):81. Available from: <http://dx.doi.org/10.1186/1477-7525-1-81>.
- [104] Reliability and validity of the Infant and Toddler Quality of Life Questionnaire (ITQOL) in a general population and respiratory disease sample. *Qual Life Res*. 2006 Nov; Available from: <http://dx.doi.org/10.1007/s11136-006-9134-8>.
- [105] Aitken ME, Tilford JM, Barrett KW, Parker JG, Simpson P, Landgraf J, et al. Health status of children after admission for injury. *Pediatrics*. 2002 Aug;110(2 Pt 1):337–342.
- [106] Polderman KH, Joe RTT, Peerdeman SM, Vandertop WP, Girbes ARJ. Effects of therapeutic hypothermia on intracranial pressure and outcome in patients with severe head injury. *Intensive Care Med*. 2002 Nov;28(11):1563–1573. Available from: <http://dx.doi.org/10.1007/s00134-002-1511-3>.
- [107] Bloch EC, Ginsberg B, Binner RA. The esophageal temperature gradient in anesthetized children. *J Clin Monit*. 1993 Apr;9(2):73–77.

- [108] Calle PA, Buylaert WA, Vanhaute OA. Glycemia in the post-resuscitation period. The Cerebral Resuscitation Study Group. Resuscitation. 1989;17 Suppl:S181–8; discussion S199–206.
- [109] Mackenzie CF. A review of 100 cases of cardiac arrest and the relation of potassium, glucose, and haemoglobin levels to survival. West Indian Med J. 1975 Mar;24(1):39–45.
- [110] Longstreth WT, Diehr P, Inui TS. Prediction of awakening after out-of-hospital cardiac arrest. N Engl J Med. 1983 Jun;308(23):1378–1382.
- [111] Longstreth WT, Inui TS. High blood glucose level on hospital admission and poor neurological recovery after cardiac arrest. Ann Neurol. 1984 Jan;15(1):59–63. Available from: <http://dx.doi.org/10.1002/ana.410150111>.
- [112] Longstreth WT, Copass MK, Dennis LK, Rauch-Matthews ME, Stark MS, Cobb LA. Intravenous glucose after out-of-hospital cardiopulmonary arrest: a community-based randomized trial. Neurology. 1993 Dec;43(12):2534–2541.
- [113] ECC Committee S, of the American Heart Association TF. 2005 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care, Part 7.5: Postresuscitation Support. Circulation. 2005 Dec;112(24 Suppl):IV84–88.
- [114] van den Berghe G, Wilmer A, Hermans G, Meersseman W, Wouters PJ, Milants I, et al. Intensive insulin therapy in the medical ICU. N Engl J Med. 2006 Feb;354(5):449–461. Available from: <http://dx.doi.org/10.1056/NEJMoa052521>.
- [115] van den Berghe G, Wouters PJ, Kesteloot K, Hilleman DE. Analysis of healthcare resource utilization with intensive insulin therapy in critically ill patients. Crit Care Med. 2006 Mar;34(3):612–616.
- [116] Brunkhorst F, Kuhnt E, Engel C, Meier-Hellmann A, Ragaller M, Quintel M, et al. Intensive insulin therapy in patient with severe sepsis and septic shock is associated with an increased rate of hypoglycemia - results from a randomized multicenter study (VISEP) [abstract]. Infection. 2005;33:19–20.
- [117] Vannucci RC, Brucklacher RM, Vannucci SJ. The effect of hyperglycemia on cerebral metabolism during hypoxia-ischemia

- in the immature rat. *J Cereb Blood Flow Metab.* 1996 Sep;16(5):1026–1033. Available from: <http://dx.doi.org/10.1097/00004647-199609000-00028>.
- [118] Shankaran S, Laptook A, Wright LL, Ehrenkranz RA, Donovan EF, Fanaroff AA, et al. Whole-body hypothermia for neonatal encephalopathy: animal observations as a basis for a randomized, controlled pilot study in term infants. *Pediatrics.* 2002;110(2 Pt 1):377–85.
- [119] Bernard SA, Buist M. Induced hypothermia in critical care medicine: a review. *Crit Care Med.* 2003 Jul;31(7):2041–2051. Available from: <http://dx.doi.org/10.1097/01.CCM.0000069731.18472.61>.
- [120] Palestrant D, Frontera JA, Mayer SA. Treatment of massive cerebral infarction. *Curr Neurol Neurosci Rep.* 2005 Nov;5(6):494–502.
- [121] O'Brien PC, Fleming TR. A multiple testing procedure for clinical trials. *Biometrics.* 1979 Sep;35(3):549–556.
- [122] Lan K, DeMets D. Discrete sequential boundaries for clinical trials. *Biometrika.* 1983;70:659–653.
- [123] Jennison C, Turnbull B. Group sequential methods with applications to clinical trials. Boca Raton, FL: Chapman and Hall; 2000.